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ABSTRACT 
 
 
 
Brown, Linda F., Ph.D., Purdue University, August 2011. Depression and Cancer-Related 
Fatigue: A Cross-Lagged Panel Analysis of Causal Effects. Major Professor: Silvia M. 
Bigatti. 
 
 
 
Fatigue is one of the most common and debilitating symptoms reported by cancer 
patients, yet it is infrequently diagnosed or treated. Relatively little is understood about 
its etiology in the cancer context. Recently, as researchers have begun to focus attention 
on cancer-related fatigue (CRF), depression has emerged as its strongest correlate. Few 
longitudinal studies have been done, however, to determine whether causal influences 
between the two symptoms exist. The aim of the current study was to determine whether 
depression has a causal influence on CRF and whether reciprocal effects exist. The study 
used a single-group cohort design of longitudinal data from a randomized controlled trial 
(N = 405) of an intervention for pain and depression in a heterogeneous sample of cancer 
patients. To be eligible, participants met criteria for clinically significant pain or 
depression. A hypothesis that depression would influence change in fatigue after 3 
months was tested using latent variable cross-lagged panel analysis, a structural equation 
modeling technique. A second hypothesis was that fatigue would also influence change in 
depression over time but at a lesser magnitude. Depression and fatigue were strongly 
correlated in the sample (i.e., baseline correlation of latent variables was 0.72). Although 
the model showed good fit to the data, χ2 (66, N = 329) = 88.16, p = 0.04, SRMR = 
0.030, RMSEA = 0.032, and CFI = 1, neither cross-lagged structural path was significant. 
The findings suggest that depression had no causal influence on changes in fatigue in this 
sample, and fatigue did not influence change in depression. The clinical implication is 
that depression treatment may not be helpful as a treatment for CRF and therefore 
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interventions specifically targeting fatigue may be needed. Future research should include 
additional waves of data and larger sample sizes. 
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INTRODUCTION 
 
 
 
Fatigue is a vexing problem in individuals with cancer. It is the most common 
symptom reported by cancer patients (Berger et al., 2009), adds considerably to suffering, 
and exists across all types and stages of the disease. It has been found to be a problem 
before, during, and after treatment, sometimes continuing long after treatment has ended, 
even in those believed to be free of disease (Hofman, Ryan, Figueroa-Moseley, Jean-
Pierre, & Morrow, 2007). Cancer-related fatigue (CRF) has been reported by up to 40% 
of patients at diagnosis, by 90% of patients receiving radiation treatment, and 80% of 
those undergoing chemotherapy (Hofman et al., 2007). Cancer patients’ experience of 
fatigue has been found to be significantly higher than healthy comparison groups with no 
cancer history, both during treatment and after it has ended (Prue, Rankin, Allen, Gracey, 
& Cramp, 2006). In research in patients with advanced cancer, fatigue is one of the most 
common and disabling symptoms (Chan, Richardson, & Richardson, 2005; Curt et al., 
2000; Higginson, Armes, & Krishnasamy, 2004; Respini, Jacobsen, Thors, Tralongo, & 
Balducci, 2003). In view of its prevalence and detrimental impact on quality of life, CRF 
is an important symptom to target in treatment. 
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BACKGROUND 
 
 
 
Until recently, CRF was infrequently discussed or treated, partly because of focus 
on other symptoms such as pain, nausea, and vomiting, and partly because fatigue was 
considered an unavoidable symptom to be endured rather than treated (Higginson et al., 
2004). Advances in cancer treatments have resulted in greater numbers of survivors who 
live many years beyond the end of treatment (Valentine & Meyers, 2001) and as a result, 
more attention must be directed to the quality of life of survivors and the associated 
effects of symptoms such as fatigue. Fortunately, fatigue has recently caught the attention 
of cancer researchers seeking to better understand its nature in order to develop effective 
interventions. A recent state-of-the-science statement from the National Institute of 
Health (NIH) called for more efforts toward symptom management in cancer, with 
fatigue named specifically along with pain and depression as the symptoms needing 
attention (Patrick et al., 2002). Based on a panel’s evaluation of available evidence, the 
report called for adequately funded prospective research focused on the definition, 
occurrence, assessment, and treatment of these symptoms and their interrelationships. 
The current study focuses on interrelationships between two of the three 
symptoms in the NIH call to action—fatigue and depression. Psychological symptoms 
have been found to have strong associations with CRF. In fact, depression’s relationship 
to fatigue has been shown to be even stronger than that of disease activity as measured by 
such markers as nutritional status and tumor-specific tests (Hotopf, 2004). Understanding 
the nature of this relationship, however, has proven elusive. Does a cancer patient 
become depressed because of the effects of being fatigued or might it be the reverse? 
Might there be bidirectional influences? Are there external factors that independently 
cause both fatigue and depression? Research to date has made little progress in teasing 
the relationships apart. Adding to the challenge is the issue of individual differences. 
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Besides the differences inherent in each person, each case of CRF carries with it a 
particular combination of cancer type, stage, type and phase of treatment, and prognosis. 
The current study was undertaken to extend the understanding of the relationship 
of depression and CRF in a way that will inform the development of effective treatment 
of these symptoms in cancer patients. It is important to know whether reductions in 
depression lead to decreased CRF, if the reverse might be true, and to what degree effects 
are bidirectional. A predominant effect in one direction (i.e., depression improvement 
accounting for much of the improvement in fatigue) might support a “treat depression 
first” strategy. In contrast, a bidirectional relationship might suggest interventions that 
either treat fatigue and depression as a cluster (i.e., treatments that have proven effective 
for both symptoms) or that comprise “dual-diagnosis” treatments (i.e., fatigue-specific 
therapy coupled with depression-specific therapy). 
 
 
 
Cancer-Related Fatigue 
Fatigue is not only the most common symptom in cancer patients (Berger et al., 
2009), it is also generally acknowledged in the literature as one of the most debilitating of 
symptoms. In several studies, CRF was rated as more troublesome and detrimental to 
quality of life (QoL) than other cancer-related symptoms including pain, depression, and 
nausea (Hofman et al., 2007). Perhaps most troubling is the fact that CRF sometimes 
persists for months or even years after treatment is completed (Hofman et al., 2007; Prue 
et al., 2006). It is highly subjective and its etiology is complex and multidimensional 
(Mustian et al., 2007; Ryan et al., 2007). People with cancer typically experience fatigue 
differently from those in the general population. In a healthy person, fatigue serves as a 
signal to rest and is a protection from overexertion, which could lead to injury or illness. 
It abates after an appropriate period of rest (Ryan et al., 2007). In contrast, CRF is an 
unpleasant sensation often accompanied by cognitive and emotional distress and 
frustration. Compared to normal fatigue, it tends to be more intense and severe, of longer 
duration, and is not relieved by adequate rest (Wu & McSweeney, 2004).  
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Characteristics and Correlates of CRF 
CRF has been defined as “a distressing, persistent, subjective sense of physical, 
emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment 
that is not proportional to recent activity and interferes with usual functioning” (Berger et 
al., 2009, p. FT-1). It is subjectively experienced by some individuals as physical 
tiredness; others experience it as a need to reduce activity, a reduction in motivation, or a 
feeling of mental fatigue (Ryan et al., 2007). CRF can adversely affect cognitive 
function; on the other hand, impaired cognitive function may lead to fatigue (Valentine & 
Meyers, 2001).  
The mechanisms of CRF are not well understood, but it is known to occur both as 
a consequence of the cancer itself and as a side effect of treatment. In some cases, CRF 
emerges as an early symptom of the disease; in others it may be a side effect of 
chemotherapy, radiotherapy (RT), bone marrow transplantation, or biological response 
modifier treatment (Berger et al., 2008; Hofman et al., 2007). The degree to which 
fatigue is caused by the cancer itself, its treatments, or interactions of the two is unknown 
but important (Andrews, Morrow, Hickok, Roscoe, & Stone, 2004). The presence of 
comorbid conditions such as anemia, cachexia, sleep disorders, and depression can be a 
complicating factor (Ryan et al., 2007).  
Three recent reviews summarized evidence regarding the prevalence, correlates, 
and patterns of CRF (Lawrence, Kupelnick, Miller, Devine, & Lau, 2004; Prue et al., 
2006; Servaes, Verhagen, & Bleijenberg, 2002). Prue and colleagues (2006) reviewed 44 
studies that used multidimensional measures of CRF, 32 of which were longitudinal. 
Lawrence and colleagues (2004) reviewed 27 studies that were relevant to occurrence of 
CRF, 56 that were relevant to assessment, and 10 randomized controlled trials (RCTs) of 
interventions for CRF. The reviewers found fatigue’s correlation with psychological 
distress—depression in particular—to be a “common theme” in several studies. In a 
review of 54 studies, Servaes and colleagues (2002) found that most studies of CRF 
focused on its association with depression. A summary of key findings of the reviews is 
presented at Appendix A. All three reviews concluded that CRF is correlated with 
depression and anxiety, as well as other symptoms such as sleep disruption, pain, and 
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shortness of breath. Findings were mixed and unclear as to CRF’s association with 
biological markers and disease and treatment factors. The majority of studies reviewed 
found no relationship between fatigue and demographic variables. Two of the reviews 
reported finding a few studies supporting age and gender relationships, and the other 
review concluded there is no relationship. 
CRF has been found to be associated with behavior. Physical activity is inversely 
correlated with fatigue. In fact, reduced activity and lack of motivation are hallmarks of 
CRF and the resulting inactivity likely serves to perpetuate the fatigued condition 
(Ahlberg, Ekman, Gaston-Johansson, & Mock, 2003). The deconditioning (i.e., loss of 
physical fitness) that follows inactivity has generally been recognized as a “potent cause” 
of fatigue in chronic fatigue patients and other medical conditions (Wessely, Hotopf, & 
Sharpe, 1998), and such effects have been found in studies with breast cancer patients 
(Ahlberg et al., 2003). As a fatigued individual becomes increasingly deconditioned over 
time, energy and motivation to resume activity that could halt the deconditioning process 
diminishes, resulting in a vicious, perpetuating cycle that is difficult to correct. Fatigue 
has been found to have a profound and pervasive impact on cancer patients’ ability to 
perform activities of daily living. Moreover, the decreased motivation to engage in usual 
activities may lead to impaired social and occupational functioning. (Hofman et al., 
2007). 
In terms of cognitive variables, catastrophizing and rumination appear to play a 
role in patient’s adjustment to cancer (Schroevers, Kraaij, & Garnefski, 2008), and a 
body of research has found consistent support for a connection between catastrophizing 
and higher levels of fatigue (Andrykowski, Schmidt, Salsman, Beacham, & Jacobsen, 
2005; Broeckel, Jacobsen, Horton, Balducci, & Lyman, 1998; Donovan, Small, 
Andrykowski, Munster, & Jacobsen, 2007; Jacobsen, Andrykowski, & Thors, 2004). 
Catastrophizing has been defined as dwelling on the most extreme negative consequences 
conceivable when confronted with a situation in which there is any possibility of an 
unpleasant outcome (Beck, 1979). This negative ruminative focus, which has been 
characterized by an analytical evaluative self-focus (i.e., thinking about the causes, 
meanings, and consequences of an event) is associated with negative affect (Rimes & 
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Watkins, 2005), which could play a role in the development and maintenance of CRF. In 
a study of 288 women undergoing adjuvant therapy for early-stage breast cancer, a 
tendency to catastrophize in response to fatigue or treatment was associated with 
incidents of CRF at post-treatment assessment. In fact, each 1-point increment of self-
reported catastrophizing was associated with a 14% increase in risk for developing CRF 
over the course of adjuvant therapy (Andrykowski et al., 2005).  
A related cognitive process that has been found to be significantly associated with 
CRF in at least one study is negative beliefs about activity. Young and White (2006) 
investigated a cognitive-behavioral model of fatigue in a sample of 69 disease-free breast 
cancer patients. The model was derived from work in CFS suggesting that the inactivity 
that maintains fatigue is associated with a belief that activity should be avoided to prevent 
worsening of the underlying cause of the fatigue. In Young and White’s study, negative 
beliefs about activity emerged as a significant predictor of CRF in regression analysis. 
This finding, although preliminary and limited by the small sample size, suggests that 
beliefs about activity may be an important perpetuating factor of CRF.  
Sleep disturbance is another prevalent and undertreated symptom in cancer 
patients that, not surprisingly, has been found to have a clear association with fatigue. 
Reviewers of the extant studies of the associations of the two symptoms have concluded 
that, although more research is needed, it is likely that sleep and CRF are reciprocally 
related. These reviewers stated that targeting either symptom in treatment may help with 
the other (Roscoe et al., 2007). A recent review of 34 studies reporting associations of 
CRF to insomnia found an average correlation of 0.34 (Donovan & Jacobsen, 2007). The 
authors concluded evidence supports assessing and treating fatigue, depression, and 
insomnia together as a symptom cluster in cancer patients.  
Notably, cognitive and behavioral variables that have been found to be associated 
with fatigue—catastrophizing, negative ruminative focus, sleep disturbance, and reduced 
activity—are also frequently included in cognitive-behavioral models of depression 
(Beck, 1979; Hollon, Haman, & Brown, 2002). 
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Assessing CRF 
Fatigue is by nature a subjective symptom and therefore it is most often measured 
by self report. To an individual suffering from it, CRF is a symptom that is “felt” rather 
than objectively manifested (Krishnasamy & Field, 2004), and participants in qualitative 
studies have reported that fatigue affected them physically, mentally, socially, and 
emotionally (Armes, 2004). Individuals who experience CRF have found it relatively 
easy to convey the physical or functional aspects but making the emotional and 
psychosocial aspects accessible to others has been more difficult (Krishnasamy & Field, 
2004). Krishnasamy included the following statement of a case study participant to 
illustrate this difficulty: 
It’s hard to tell you or tell really anyone what it’s like because it’s something that 
you feel all over, inside and outside…it’s like pulling down inside when you have 
to fight even to stand up. Some days it’s hard to imagine I will ever be able to do 
anything again and I can feel myself in danger of just giving up, that’s what it’s 
like, but I don’t know if that makes sense to you or anyone but me (p. 130). 
Some scientists have proposed that CRF is best assessed as a syndrome. 
Consequently, a standard set of diagnostic criteria has been added to the recently revised 
ICD-10 (International Statistical Classification of Diseases and Related Health 
Problems--10th Revision, 2007). To meet criteria, a cancer survivor must experience at 
least 6 of 11 symptoms and meet three other requirements, one of which is that the 
symptoms are not related to a comorbid condition such as major depression (Cella, Davis, 
Breitbart, & Curt, 2001). These criteria have not yet achieved expert consensus or 
validation, however, and most research studies simply measure fatigue, either in a simple 
or multidimensional fashion. 
A review of the literature on CRF measurement (Wu & McSweeney, 2004) 
reported having found evidence that health professionals are increasingly receptive to 
assessing CRF and incorporating the patients’ perspective in that assessment. Work has 
expanded in the development of multidimensional measures of CRF to go along with 
simple, single-item screening measures, and both existing and new measures are being 
psychometrically tested and revised. A continuing problem, however, is lack of 
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consensus on the definition of CRF and which measurement approach is best. A recent 
review (Jean-Pierre et al., 2007) found 26 different scales that had been used to assess 
CRF, some of which were developed specifically for cancer fatigue and some of which 
were non-specific to cancer. 
 
 
 
Biological Mechanisms of CRF 
Although potential biological mechanisms have been proposed, relatively little 
basic research to date has focused on fatigue in general and even less on CRF (Gutstein, 
2001). Andrews and colleagues (2004) noted that CRF’s complexity and 
multidimensional nature makes it a difficult symptom to study. Moreover, fatigued 
patients can be especially difficult to recruit for research participation—and those who do 
participate may be suffering detrimental effects on concentration or attention that may 
interfere with research activities. The consequent dearth of empirical evidence regarding 
the physiological mechanisms of CRF has led to a reliance on descriptive and 
correlational studies to inform treatment. Extant conceptualizations of possible 
mechanisms are mostly derived from research carried out in non-cancer populations in 
the context of physical exercise or diseases other than cancer such as chronic fatigue 
syndrome (CFS) and rheumatoid arthritis (Ryan et al., 2007). CRF differs substantially 
from the fatigue associated with exercise, which is readily relieved by rest (Andrews et 
al., 2004). Fatigue experienced by cancer patients may have more in common with the 
experience of those diagnosed with CFS, although differences as well as similarities have 
been noted by the few investigators who have addressed this issue (Bennett, Goldstein, 
Friedlander, Hickie, & Lloyd, 2007; Servaes, van der Werf, Prins, Verhagen, & 
Bleijenberg, 2000; Wessely et al., 1998).  
Biological mechanisms that have been proposed for CRF include dysregulation of 
cytokines, hypothalamic-pituitary-adrenal (HPA) axis dysfunction, abnormal 
accumulation of muscle metabolites, changes in neuromuscular function, abnormalities in 
adenosine triphosphate synthesis, serotonin dysregulation, vagal afferent activation, and 
circadian rhythm dysfunction (Berger et al., 2008; Ryan et al., 2007). A recent review 
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(Miller, Ancoli-Israel, Bower, Capuron, & Irwin, 2008) reported that immunologic 
processes have been receiving special attention in the search for mechanisms to explain 
what they characterized as “behavioral alterations” but are in essence symptoms (i.e., 
depression, fatigue, sleep disturbance, and cognitive dysfunction) common in patients 
with cancer. The authors presented data indicating that increased inflammatory responses 
triggered by cancer and its treatments may interact with pathophysiologic pathways 
known to be involved in the regulation of common cancer-related symptoms. 
Specifically, activation of innate immune inflammatory response and its regulation 
through neuroendocrine pathways are hypothesized to influence CNS functions including 
neurotransmitter metabolism, neuropeptide function, sleep-wake cycles, and regional 
brain activity. The ultimate result may be mediation of the development of fatigue, 
depression, impaired sleep, and cognitive dysfunction. The review included discussion of 
studies finding an association between inflammatory markers and fatigue in cancer 
patients and compared these to other studies reporting negative findings. The authors 
concluded that alterations in cortisol secretion in response to the stress of cancer may 
play a role in inflammatory dysregulation which may be a mechanism underlying fatigue. 
They also cited a recent meta-analysis as further support for their model (Schubert, Hong, 
Natarajan, Mills, & Dimsdale, 2007). The meta-analysis authors pooled correlation 
coefficients from 18 studies and found that CRF was positively associated with 
inflammatory markers. 
 
 
 
Depression in Cancer 
Depression occurs in about 10% to 25% of people with cancer, a rate estimated to 
be at least four times greater than in the general population (Carr et al., 2002; Pirl, 2004) 
but similar to rates of depressive states in patients similarly ill with other medical 
diagnoses (Spiegel & Giese-Davis, 2003). Prevalence rates in cancer patients have been 
found to be similar whether depression is identified as a set of symptoms or as a clinical 
syndrome such as a major depressive disorder (MDD). A recent review (Pirl, 2004) 
concluded that a majority of studies diagnosing MDD as a syndrome using Diagnostic 
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and Statistical Manual of Mental Disorders (DSM) criteria found rates of between 10% 
and 25%; a majority of studies using a standardized instrument to measure prevalence of 
depressive symptoms fell into the range of 7% to 21%. Some of the variance across 
studies was attributed to heterogeneity in the population samples in terms of cancer type, 
hospital status, disease or treatment status, and differences among authors in choosing 
cutoff scores. 
Risk of developing depression in cancer patients may vary by type of treatment 
(Raison & Miller, 2003). Certain cytokines and other cancer-related medications are 
frequently associated with depression. Some evidence suggests oncologic surgery may 
also increase the risk of developing depression. 
 
 
 
An Overlooked Symptom 
Similarly to fatigue, depression has been under-diagnosed and undertreated in 
cancer patients (Bottomley, 1998; Spiegel & Giese-Davis, 2003). Evidence suggests that 
depression may go unrecognized by internists treating medically ill outpatients in 50% to 
75% of cases (McDaniel, Musselman, Porter, Reed, & Nemeroff, 1995). Depression may 
be overlooked partly because the symptoms are considered to be a normal and inevitable 
reaction to serious disease and partly because some of the signs of depression (e.g., 
weight loss and sleep disturbance) can also be attributed to the disease itself (Raison & 
Miller, 2003; Spiegel & Giese-Davis, 2003). Recognizing and treating depression is 
considered crucial in medically ill patients, however, not only to enhance quality of life 
but because it may adversely affect compliance with treatment, length of time in the 
hospital, and ability for self-care (McDaniel et al., 1995). 
 
 
 
Assessing Depression 
The broad range of states and symptoms encompassed within the construct of 
depression complicates its assessment. “Depression” may refer to a mood state, the 
diagnosis of a clinical syndrome such as MDD, or it may refer to one or a group of 
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symptoms such as sad mood, anhedonia, anorexia, weight loss, and sleep disturbance 
(Ingram & Siegle, 2002; Raison & Miller, 2003). Ingram and Siegle (2002) discussed the 
arbitrariness of depression as a theoretical construct—determined as it is by a collective 
decision by the scientific community to formally recognize certain symptoms (e.g., sad 
mood) and not others (e.g., being discouraged about the future). Because of the lack of 
standardization in diagnosing depression, some have advocated assessing depression in 
medical patients through biological markers such as neuroendocrine alterations, changes 
in serotonergic neurotransmission, alterations in sleep architecture, or structural brain 
abnormalities. However, no biological marker has yet been identified to be sensitive and 
specific enough for depression diagnosis, and few studies have taken up this assessment 
method (Massie & Popkin, 1998). 
The clinical interview is considered standard for diagnosing MDD in cancer 
patients. As for assessing depressive symptoms, no clear standard has been established, 
according to the findings of a recent review, although the Hospital Depression and 
Anxiety Scale (HADS) was used most frequently to measure depressive symptoms (Pirl, 
2004). Many instruments are in use, some of which were created for cancer patients, and 
they range in complexity from simple visual analog scales to multidimensional 
instruments including quality-of-life assessment. In research, depression is often 
operationally defined as scoring above a cutoff score on a self-report questionnaire 
(Ingram & Siegle, 2002). 
Assessment of depression in cancer patients is confounded by physical symptoms 
that are associated with both depression and the disease or its treatment (Pirl, 2004). 
Raison and Miller (2003) discussed the overlap of depressive symptoms with those often 
observed in the context of illness such as cancer. To illustrate the scope of the problem, 
these authors listed 13 signs and symptoms, 9 of which were common to both major 
depression and cytokine-induced sickness behavior (often present in cancer patients). The 
symptoms common to both were anhedonia, social isolation, fatigue, anorexia, weight 
loss, sleep disturbance, cognitive disturbance, decreased libido, and psychomotor 
retardation. Hyperalgesia (i.e., increased sensitivity to pain) distinguished sickness 
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syndrome from depression, and symptoms that help to distinguish major depression were 
depressed mood, guilt/worthlessness, and suicidal ideation. 
The problem of overlap of symptoms across clinical syndromes extends to the 
current study in important ways. The fact that fatigue is a symptom of sickness behavior 
and also depression poses special challenges in efforts to understand the interrelationship 
of CRF and depression.  
 
 
 
Associations of CRF and Depression 
Fatigue and depression are symptoms of similar importance in cancer care, as 
both conditions occur more frequently in cancer patients than in the general population 
and both can be highly distressing and disabling. With the recent emphasis on assessing 
and treating CRF, researchers and clinicians need to better understand how fatigue and 
depression interrelate in the cancer context. It is well established that fatigue is both a 
symptom of certain depressive disorders and a symptom of cancer and its treatment. It is 
also generally known that depression is, like fatigue, often present in patients with cancer. 
Beyond that, many aspects of the relationship require clarification through future 
investigation. For example, to what degree do fatigue and depression conceptually differ, 
to what degree do they co-occur, and are there causal relationships (Jacobsen, Donovan, 
& Weitzner, 2003)? In terms of treatment, does intervening on depression lead to relief 
from fatigue as well? The answers to these questions will ultimately aide both researchers 
and clinicians who are seeking better ways to assess and treat fatigue in cancer care 
settings. 
Extant literature reveals significant correlations between fatigue and depression in 
cancer patients—sometimes at a relatively strong magnitude. For example, Jacobsen and 
colleagues (2003) conducted a review of CRF’s association with depression. In 30 studies 
that assessed both fatigue and depression in patients with cancer, correlations between the 
two were all positive and ranged from 0.16 to 0.80. The average correlation across 
studies was 0.54. Another review focused on fatigue, depression, and insomnia as a 
potential symptom cluster, assessing the data from 16 studies that measured all three 
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symptoms (Donovan & Jacobsen, 2007). The correlations found for fatigue and 
depression were strikingly similar to that found by Jacobsen and Weitzner, with the 
average being 0.55, and a range of 0.16 to 0.80. 
Elucidation of the other questions about the nature of the relationship between 
CRF and depression, however, is more limited in the literature. In fact, Jacobsen and 
colleagues (2003) found contradictory evidence regarding causal relationships in their 
review of 30 studies. They concluded some of the evidence suggested CRF could cause 
depression, some suggested that depression can cause CRF, and some indicated that both 
CRF and depression are caused by a common third factor. 
Because the conceptual overlap and extent of co-occurrence of fatigue, 
depression, and anxiety is so pronounced, some authors have even examined the 
possibility that general fatigue (not necessarily in cancer patients) and psychiatric 
disorder (i.e., depression and anxiety) are actually one and the same (Reuter & Härter, 
2004; Van Der Linden et al., 1999; Wessely et al., 1998). Wessely and colleagues (1998), 
who were primarily focusing on chronic fatigue syndrome, advanced an opposing 
argument that fatigue sometimes exists independently of psychiatric disorder. 
Reuter and Härter (2004) mapped the multidimensional factors of fatigue as 
conceptualized in oncology settings against recognized factors of depression, placing 
them in categories of physical (i.e., loss of energy, decreased activity, decreased 
energy/tiredness, physical sensations, somatic/vegetative symptoms, sleep disturbance, 
and weakness); cognitive (i.e., decreased concentration and attention and loss of interest); 
and emotional (i.e., sadness, anxiety/tension, depressed mood/anhedonia, and 
psychomotor retardation or agitation), as presented in Table 1. They concluded that 
fatigue did not comprise any symptoms beyond those found in the context of depression, 
and that depression is the broader—possibly even subsuming—concept. Depression, they 
argue, extends beyond fatigue because of its unique cognitive and emotional aspects such 
as self-devaluation, feelings of emptiness and deadness, fear of the future, social 
withdrawal, and suicidal ideation. Taking into account the evidence found in studies 
relating to CFS suggesting fatigue as an entity independent of depression, these authors 
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advocated further exploration of the degree of independence between the two diagnostic 
entities for the potential to inform treatment for cancer patients. 
 
 
 
Measurement Challenges 
Measurement is an important issue in the study of the relationship between CRF 
and depression, particularly the ability to distinguish fatigue from depression. Both are 
heterogeneous constructs with physical, cognitive, and emotional dimensions and a high 
degree of overlap across the dimensions. For example, “fatigue or loss of energy nearly  
 
Table 1 
Symptoms of Fatigue and Depressive Disorders 
 
Fatigue Depressive Disorders 
 
Physical 
Decreased activity Loss of energy 
Decreased energy/tiredness Loss of energy 
Weakness Loss of energy 
Physical sensations Somatic-vegetative symptoms 
Sleep disturbance Sleep disturbance 
 
Cognitive 
Decreased concentration and 
attention 
Decreased concentration and 
attention 
Loss of interest Loss of interest 
 
Emotional 
Sadness Depressed mood, anhedonia 
Anxiety/tension Psychomotor retardation or agitation 
 
(Reuter & Härter, 2004) 
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every day” is one of the core symptoms used in establishing a clinical diagnosis of 
depression (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Text 
Revision, 2000, p. 356). Both depression and fatigue can be assessed as a single 
symptom, a cluster of symptoms, or as a clinical syndrome (Arnold, 2008). Both are 
measured primarily by self report. Diagnostic criteria for depressive syndrome share 
several symptoms in common with the syndromal diagnostic criteria for CRF including 
fatigue, sleep disturbance, concentration difficulties, and decreased interest in usual 
activities. 
The generally high positive correlations found on continuous measures of fatigue 
and depression administered together have led some to question the discriminant validity 
of the instruments in use (Jacobsen, 2004). However, some studies have found that the 
correlation of fatigue and depression remains high even after removing the fatigue items 
from depression measures (Smets, Garssen, Cull, & de Haes, 1996; Stone, Hardy, 
Huddart, A., & Richards, 2000; Stone, Richards, A'Hern, & Hardy, 2001). Furthermore, 
fatigue measures correlate rather strongly with measures that assess just the mood aspects 
of depression (Jacobsen & Weitzner, 2004). Some have suggested that the overlap 
problem may be avoided in fatigue assessment by use of a single-item measure in which 
patients are asked to rate fatigue experience on a 1-to-10 scale, such as “to what degree 
have you experienced fatigue during the past week?” (Jean-Pierre et al., 2007). Others 
have proposed that CRF is best measured as a syndrome, using the set of diagnostic 
criteria that has been proposed for future inclusion in the International Classification of 
Diseases Tenth Edition (Cella et al., 2001).  
Because measurement may confound attempts to understand the relationship 
between CRF and psychological variables, it was included as a secondary topic in a 
systematic review of studies undertaken during development of the current study (Brown 
& Kroenke, 2009). Anxiety correlations are also included in the review because no 
previously published systematic review has reported anxiety’s association with CRF even 
though many investigators have included analysis of anxiety as an adjunct to 
investigating depression’s associations with fatigue in cancer. 
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Systematic Review of Associations of CRF with Depression and Anxiety 
In a systematic review of the literature (Brown & Kroenke, 2009), studies were 
included that reported the associations of CRF with depression or anxiety or both. 
Associations were reported either as correlation coefficients or odds ratios. Tabulated 
summary information for each study can be found in Appendix B. 
The total number of participants from 61 studies was 12,704. Depression was 
significantly related to CRF in all the studies that reported the association except one, and 
in some cases the magnitude was strong. The range of correlation coefficients between 
fatigue and depression in 52 studies reporting this statistic was 0.16 to 0.84. The average 
correlation, weighted by sample size, was 0.56 (95% CI, 0.54 to 0.58). For the three 
studies reporting odds ratios, the weighted average association of fatigue with depression 
was 1.16.  
Anxiety was significantly correlated to fatigue in 33 of the 35 studies reporting 
the association. The range of correlation coefficients was 0.16 to 0.73, and the weighted 
average was 0.46 (95% CI, 0.44 to 0.49). The weighted mean for the two studies 
reporting odds ratios was 1.19.  
Thirty-one different instruments were used to assess fatigue in the 61 studies in 
the review, demonstrating the lack of consensus about the best way to measure fatigue in 
cancer research. No single scale predominated. The instrument used most frequently, the 
Multidimensional Fatigue Inventory, was used in only 9 studies. In contrast, depression 
was measured with 12 instruments across all the studies. Two scales predominated for 
measuring depression—a subscale of the HADS (Zigmond & Snaith, 1983) was used in 
24 studies, and the Center for Epidemiological Studies Depression Scale (CES-D; 
Radloff, 1977) was used in 15.  
A few investigators addressed the issue of measurement overlap between fatigue 
and depression by dropping certain items from depression instruments that were 
identified as most likely to reduce discrimination of separate constructs. Dropped items 
typically assessed physical or somatic symptoms or were otherwise deemed as similar to 
fatigue (e.g., “I feel as if I am slowed down”). Significant relationships were found in all 
the studies that dropped items except one. 
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Twenty-five of the studies were longitudinal. Of these, 17 investigated 
associations between fatigue and depression or anxiety at multiple time-points. These 
studies were examined for patterns to explicate the interrelationships between fatigue and 
depression. No clear pattern was identified, partly due to heterogeneity of the samples 
between studies and partly due to inconclusive or contradictory findings. In only 2 studies 
did the authors clearly assert that their findings suggest that changes in fatigue were 
associated with changes in depression and anxiety (Stone et al., 2001; Tchekmedyian, 
Kallich, McDermott, Fayers, & Erder, 2003). Authors of at least 6 studies concluded that 
no evidence of relationships with longitudinal changes in fatigue had been found—4 of 
which referred to depression but not anxiety (Morrow et al., 2003; Pirl, 2008; 
Schumacher et al., 2002; Visser & Smets, 1998), and 2 assessing both depression and 
anxiety (Geinitz et al., 2001; Stone, Hardy et al., 2000). Authors of the remaining studies 
reported findings that were relatively ambiguous on this matter. 
The 8 studies that did report conclusions about longitudinal relationships between 
fatigue and depression are particularly germane to the current study and therefore warrant 
further elucidation. Stone and colleagues (2001) studied fatigue, depression, and anxiety 
in patients with breast cancer (n = 34) or prostate cancer ( n = 35) before RT and within a 
week after treatment completion. Of 5 fatigue measures, 3 showed a significant increase 
in fatigue over the course of RT. Small but significant increases in depression scores 
were associated with small increases in fatigue scores. A combination of fatigue and 
anxiety scores at baseline was able to predict 54% of the variation in fatigue scores at the 
completion of RT. It is important to note, however, that the scale that was designated a 
priori as the primary fatigue measure (the Fatigue Severity Scale) failed to demonstrate a 
significant increase. Moreover, while the increases shown by 3 other measures of fatigue 
were significant, the magnitude of change was relatively modest. These two issues cast 
doubt on the findings.  
The other study that found associations between changes in fatigue and changes in 
depression was with a sample of patients receiving chemotherapy for lung cancer (n = 
250) and participating in a randomized, double-blind, placebo-controlled trial of 
darbepoetin alfa for treatment of anemia. The participants were assessed for fatigue, 
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depression, and anxiety at baseline and between the 4th and 12th week of treatment 
(Tchekmedyian et al., 2003). Improvements in fatigue were associated with reductions in 
anxiety and depression.  
One of the studies finding no associations between changes in fatigue and changes 
in depression was that of Morrow and colleagues (2003). In this randomized, double-
blind placebo-controlled trial involving 549 cancer patients undergoing chemotherapy, 
depression was affected by the intervention (paroxetine compared to placebo) while 
fatigue was not. In a study of 52 men with prostate cancer receiving hormone therapy 
(Pirl, 2008), fatigue increased significantly over the 12-month study period but 
depression did not change. In another study, Schumacher and colleagues (2002) 
evaluated QoL in 101 patients undergoing treatment for acute myeloid leukemia. 
Assessment was done at 12 time-points. Depression was significantly inversely correlated 
with the emotional functioning subscale of the European Organization for Research and 
Treatment of Cancer QLQ-C30 throughout the study but its correlation with the fatigue 
subscale was nonsignificant at 5 of 12 time-points.  
Another study that found no evidence for a cause-and-effect relationship between 
fatigue and depression was that reported by Visser and Smets (1998). These researchers 
examined a heterogeneous sample of 250 cancer patients before treatment, two weeks 
after treatment, and nine months after treatment. Fatigue remained stable or increased just 
after radiotherapy, depending on the dimension being considered, whereas depression 
decreased. Nine months later, fatigue had decreased while depression remained stable. In 
another study of 41 breast cancer patients (Geinitz, 2001), fatigue increased during RT 
and returned to pretreatment levels 2 months after treatment. Although anxiety and 
depression were found to be associated with fatigue, neither the anxiety nor the 
depression scores increased significantly during RT, arguing against these variables 
explaining radiation-related fatigue.  
The sixth study that found no relationship between changes in fatigue and changes 
in depression was reported by Stone and colleagues (2000). They examined fatigue in 62 
outpatients with prostate cancer before hormone therapy treatment and 3-months after 
treatment. They noted that increases in fatigue were not related to any increase in 
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psychological complaints, including depression, even though a strong relationship existed 
at baseline. 
Our own review (Brown & Kroenke, 2009) concluded that depression and anxiety 
are both important correlates of CRF, with depression having the stronger association of 
the two. The findings supported the conclusions of previous reviews of psychological 
correlates of CRF (Donovan & Jacobsen, 2007; Jacobsen et al., 2003; Jacobsen & 
Weitzner, 2004; Servaes, Verhagen et al., 2002). The heterogeneity of the 61 studies, 
however, precluded specific conclusions about the directionality or mechanisms 
underlying the relationships among fatigue and depression. Moreover, the inconsistent 
findings in the subset of longitudinal studies support suggestions in the literature that 
development of CRF may involve several physiological, biochemical, and psychological 
systems (Ryan et al., 2007) that may vary by cancer site, stage of disease, and type of 
treatment. 
Intervention studies aimed at improving outcome variables that are correlated 
with CRF may also be helpful in teasing apart the interrelationships (Hotopf, 2004). For 
example, an intervention that improves cancer-related depression could be evaluated in 
terms of its concomitant effect on fatigue. Conversely, interventions targeting fatigue 
could be analyzed for effects on depression and anxiety. The study by Tchekmedyian and 
colleagues (2003) is one such example, and it has provided the single most compelling 
finding suggesting that changes in fatigue are associated with changes in depression. 
These findings are contradicted, however, by the randomized, double-blind placebo 
controlled trial of Morrow and colleagues (2003), in which depression was affected by 
the intervention (paroxetine compared to placebo) while fatigue was not. This trial 
specified elevated fatigue as an inclusion criterion—important in this type of research. 
The measurement challenges associated with studying CRF’s relationship to 
depression demand careful attention in future studies. Research in this domain will 
benefit if the field of fatigue instruments is narrowed to a few that have been well-
validated to accurately assess CRF and distinguish it from depression.  
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Statement of the Problem 
The current research was undertaken to add to the understanding of the nature of 
the relationship between fatigue and depression in cancer patients. Although evidence in 
the literature demonstrates a clear association between the two symptoms, studies 
examining directional or causal relationships are too few and the findings too inconsistent 
to draw conclusions. Many investigators working in this domain have called for more 
longitudinal research in cancer patients who report symptoms of fatigue and depression. 
They emphasize a need for careful measurement and analysis of how the relationships 
either change or stay the same over time. The current study analyzed the pathways among 
these symptoms in search of evidence suggesting possible causal relationships. 
 
 
 
A Cognitive Behavioral Model of Fatigue 
Primarily in the context of chronic fatigue syndrome, Wessely, Hotopf, and 
Sharpe (1998) proposed a cognitive behavioral model that recognizes the 
multidimensionality of persistent fatigue and distinguishes between factors that are 
predisposing, precipitating, or perpetuating. The authors supported this model by 
discussing “mutually reinforcing vicious circles” of interacting beliefs, emotions, 
physiology, and behavior hypothesized as perpetuating an extant illness such as fatigue: 
The experience of symptoms, and fears about their meaning, interfere with the 
normal physiological and psychological processes required for effortful activity or 
cognitive processes. The consequence of increased concern is heightened 
awareness, selective attention, and ‘body watching’, which can then intensify both 
the experience and perceived frequency of symptoms, thereby confirming illness 
beliefs and reinforcing illness behaviour. This in turn contributes to a vicious 
circle of increasing symptomatic distress and increasing restriction of activity in 
order to cope with such symptoms. The more activity is avoided, the worse are the 
symptoms whenever it is attempted, thus providing further validation of the 
accuracy of the person’s illness beliefs. Episodic attempts to be active merely 
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serve to strengthen the patient’s belief conviction of suffering from an 
insurmountable disease and leads to further concern about symptoms (p. 277). 
The core of the hypothesized model is the notion that what triggers an episode of fatigue 
may not be what keeps it going.  
Hotopf (2004) presented a version of this model relating it to general fatigue and 
discussed its potential for consideration in a cancer context. In his presentation, 
predisposing factors of acute fatigue included past psychiatric disorder, somatic 
attributional style, early illness experience, and genetic factors. The precipitating event 
might be a serious viral infection, life event, or surgery. Perpetuating factors in the model 
that might result in chronic fatigue included behavioral, cognitive, emotional, physical, 
and social constructs. The model itself is untested (M. Hotopf, personal email 
communication, May 30, 2008) although extant literature provides support for the 
constructs that are included. The model for the current study at Figure 1 represents a 
further adaptation of the one published by Hotopf. This modified version incorporates 
findings in the literature specific to CRF. For this study, it will be referred to as the 
perpetuating factors model, as that category of factors supports the main hypotheses. 
 
 
Figure 1. Perpetuating factors of cancer-related fatigue 
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Existing literature was surveyed for evidence about the degree to which the perpetuating 
factors model as proposed for CFS (Wessely et al., 1998) might also be applicable in a 
cancer context. At least two studies have been published comparing the experience of 
CRF with that of CFS. An investigation comparing 57 patients with fatigue after breast 
cancer treatment to 57 gender- and age-matched patients with CFS (Servaes, Prins, 
Verhagen, & Bleijenberg, 2002) found both similarities and differences between groups. 
CFS patients’ scores were more problematic in level of fatigue, functional impairment, 
physical activity, pain, and self-efficacy; however, problems were similar between the 
two groups in terms of psychological well-being, sleep, and concentration. The authors 
concluded that interventions targeting the cognitive and behavioral perpetuating factors 
of fatigue would be relevant for CRF as well as for CFS but modifications would be 
needed, possibly emphasizing depression, sleep, and concentration problems. A 
qualitative study (Bennett et al., 2007) compared the experience of 16 women with post-
cancer fatigue and 12 women with CFS. The analysis revealed that both groups reported 
“remarkably similar” symptoms featuring fatigue, cognitive difficulties, mood 
disturbance, and disabling behavioral consequences. Both groups had similar levels of 
sleep disturbance. Women with CFS reported additional symptoms of musculoskeletal 
pain and influenza-like manifestations. Mood disturbance was prominent in the 
descriptions provided by the women with CRF. The authors concluded that CRF 
appeared to be qualitatively similar to CFS.  
Another study (Vercoulin et al., 1998) presented findings relating to perpetuating 
factors of chronic fatigue, although it did not test fatigue in cancer patients. Vorcoulin 
and colleagues tested a model of hypothesized cognitive and behavioral perpetuating 
factors of fatigue using path analysis comparing CFS patients (n = 51) with patients with 
multiple sclerosis (MS; n = 50). Hypothesized perpetuating factors for fatigue included 
depression, causal attributions, sense of control, and physical activity. Results of a 
structural equation modeling analysis led the researchers to drop depression from the 
causal model and to add focusing on symptoms as a perpetuating factor, resulting in a 
good fit for the model in CFS patients but not in MS patients. The authors concluded that 
the findings of this study, along with other evidence in the literature, suggest that current 
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depression does not predict improvement in fatigue and that mood disorder is not an 
essential factor in perpetuating fatigue. Methodological problems with this study must be 
taken into account, however. The study was cross-sectional although longitudinal data is 
preferable in causal path analysis. Moreover, the sample size of 101 may have been too 
small to support the conclusions. Structural equation modeling is generally understood to 
be a large-sample technique, with 200 being the commonly accepted minimum for 
“large” samples (Kline, 2005).  
To summarize, evidence is sufficient to support the co-occurrence of fatigue and 
depression in cancer patients. Evidence also appears to support the existence of 
depression and fatigue as two independent entities in cancer patients, albeit with 
substantial overlap. The literature is inconclusive, however, about whether depression 
exerts causal effects on fatigue, fatigue exerts causal effects on depression, the symptoms 
are the result of one or more common causes, or whether some combination or interaction 
among these possibilities exists. Of 17 longitudinal studies examining the relationship, 2 
found fatigue and depression changed together in CRF, 6 found no evidence that changes 
in fatigue were associated with changes in depression, and the remaining studies were 
ambiguous on this matter. A model of fatigue proposed in the literature has hypothesized 
depression as a perpetuating factor in chronic fatigue, and a small body of evidence 
supports extending that model to a cancer context. A single study with methodological 
flaws concluded that depression is not important to perpetuation of fatigue in CFS 
patients. More longitudinal research, therefore, is warranted to determine how depression 
and fatigue are related in cancer patients.  
 
 
 
Purpose 
The current study examined the relationship of depression and fatigue over time in a 
heterogeneous sample of cancer patients. The perpetuating factors model of CRF 
provided theoretical support for the study hypotheses (Figure 1). Depression was 
expected to be supported as a perpetuating factor of fatigue by demonstrating that 
depression is causally related to fatigue. If depression is supported as a perpetuating 
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factor of CRF, then interventions targeting depressive symptoms may be appropriate in 
treating cancer patients who report they are suffering from fatigue. 
 
 
 
Study Aims 
The aim of this study was to examine whether depression exerts causal influence on 
fatigue over time in cancer patients. The existence of reverse or reciprocal effects (i.e., 
causal influence of fatigue on depression or bi-directional pathways) was also examined.  
Hypothesis 1 
In a heterogeneous sample of cancer patients, depression will predict changes in 
fatigue over 3 months. The association will be positive. 
Hypothesis 2 
Fatigue will also predict changes in depression over 3 months (reciprocal effects). 
This association will be positive but will be of lower magnitude than that between 
depression and changes in fatigue. 
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METHODS 
 
 
 
This study used a single-group cohort design in a secondary analysis of 
longitudinal data from a randomized controlled trial (N = 405) of an intervention for pain 
and depression in cancer patients. Kurt Kroenke, MD, is the principal investigator. The 
Indiana Cancer Pain and Depression trial (INCPAD) is an NCI-funded study that tested 
the effectiveness of telecare management delivered by a nurse-psychiatrist team in a 
statewide network of urban and rural community-based cancer clinics. The intervention 
was based upon the empirically-validated Three-Component Model (TCM; Dietrich et 
al., 2004; Oxman, Dietrich, Williams Jr., & Kroenke, 2002). In INCPAD, the model was 
a collaboration between the oncology practice, a centralized nurse care manager, and a 
supervising pain-psychiatrist. A telemedicine approach was utilized with automated 
home-based symptom monitoring of pain and depressive symptomatology coupled with 
telephonic nurse care management over 12 months. Medication management utilized 
evidence-based algorithms for antidepressants and analgesics. Participants were assessed 
at baseline, 1, 3, 6, and 12 months by telephone interviewers blinded to treatment group. 
The sample included patients with cancer-related pain (n = 96), clinical depression (n = 
131), or both (n = 178). Participants were randomized by computer to either the 
intervention or usual care control group, stratified by symptom type. Participants were 
enrolled from March 2006 to August 2008. Details of the study design and longitudinal 
outcomes have been published (Kroenke et al., 2009; Kroenke et al., under review). To 
summarize, patients in the intervention group had greater improvements than the usual 
care control group in both depression and pain at all time points including 12 months. 
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Participants 
Participants were recruited for the INCPAD study from 16 oncology clinics 
affiliated with the Community Cancer Care (CCC) network in Indiana. Cancer types 
included breast (29%), lung (20%), gastrointestinal (17%), lymphoma or hematological 
(13%), genitourinary (10%); and other (10%). Forty-two percent were in a maintenance 
phase or disease-free status, 37% were newly diagnosed, and 20% were experiencing 
recurrent or progressive cancer. Ages ranged from 23 to 85, with the average being 58 
(SD = 10.8). The sample was 68% female. About half (49%) were married. The majority 
were Caucasian (80%). Education was mixed: 12% were college graduates, 27% had 
attended some college or trade school, 40% had a high school diploma or GED, and 22% 
had not finished high school. Overall, the sample had a relatively low income (only 25% 
reported a “comfortable level of income”); 20% were employed, whereas 43% were 
unable to work due to health or disability, and 29% were retired. Baseline characteristics 
are further detailed in Table 2. 
Although the INCPAD sample was recruited based on clinically significant pain 
or depression, baseline data indicates a high prevalence of fatigue . In fact, in a published 
secondary analysis of somatic symptom burden in INCPAD, fatigue was reported to be 
the most bothersome symptom among the 22 symptoms assessed, with 98% of the sample 
reporting feeling tired and 79% reporting being “bothered a lot” by this symptom 
(Kroenke et al., In Press). Moreover, the mean score on the SF vitality scale was 28.26 
(SD = 19.2), which exceeded the established cutoff for clinically significant fatigue. 
 
 
 
Procedures 
To identify eligible participants for the INCPAD study, oncology clinic staff 
members asked patients to complete a 4-item depression and pain questionnaire, which is 
a combination of 2-item screeners that are both well-validated for assessing depression 
and pain severity. The PHQ-2 depression scale (Kroenke, Spitzer, & Williams, 2003) is 
drawn from the 9-item Patient Health Questionnaire (PHQ-9) and the pain screener is the 
SF-36 bodily pain scale (Ware, Kosinski, & Keller, 1994). 
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Table 2 
Baseline Characteristics 
• Bold value in range indicates  
worse score 
Full INCPAD 
sample 
N = 405 
Panel 
Analysis 
sample 
n = 329 
P 
Value 
Mean (SD) age, yr 58.8 (10.8) 
range 23 - 85 
58.5 (10.5) 
range 29 - 85 
.70 
Female sex, n (%) 275 (68) 228 (69) .61 
Race, n (%)    
     White 322 (80) 260 (79) .95 
     Black 73 (18) 61 (18) .93 
     Other 10 (2) 8 (2) .84 
Education, n (%)    
     Less than High school 87(21) 68 (21) .86 
     High school 160 (40) 131 (43) .40 
     Some college or trade school 108 (27) 89 (27) .97 
     College graduate 50 (12) 41 (12) .95 
Married, n (%) 199 (49) 159 (48) .84 
Employment status, n (%)    
     Employed 81 (20) 65 (20) .99 
     Unable to work--poor health/disability 176 (43) 148 (45) .74 
     Retired  117 (29) 92 (28) .85 
     Other 30   (7) 24 (7) .94 
Comfortable level of income, n (%) 100 (25) 81 (25) .95 
Mean (SD) no. of medical diseases 2.08 (1.6) 2.09 (1.6) .93 
Mean (SD) scores *    
SF Vitality Scale Total (score range, 0-100)    28.26 (19.2)   29.12 (19.6) .58 
     BPI pain severity (score range, 0-10) 4.27 (2.4) 4.20 (2.3) .69 
     SCL-20 depression (score range, 0-4) 1.44 (0.7) 1.43 (0.7) .85 
     Sheehan Disability Index (range, 0-10) 5.44 (2.9) 5.34 (2.9) .67 
     Overall quality of life (score range, 0-10) 5.62 (2.3) 5.67 (2.3) .82 
Mean disability days in past 4 weeks    
     Bed days 5.6 (7.7) 5.78 (7.7) .75 
     Days in which activities reduced by ≥ 50%   11.2 (9) 10.97 (9) .75 
Currently w/ mental health provider, n (%) 44  (11) 38 (12) .76 
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Baseline Characteristic 
Full INCPAD 
sample 
N = 405 
Panel Analysis 
Sample 
N = 329 
P 
Value 
Type of cancer, n (%)    
     Breast 118 (29) 106  (32) .42 
     Lung 81 (20) 60 (18) .56 
     Gastrointestinal 70 (17) 57 (17) .77 
     Lymphoma and hematological 53 (13) 41 (13) .77 
     Genitourinary 41 (10) 33 (10) .90 
     Other 42 (10) 32 (10) .94 
Phase of cancer, n (%)    
     Newly-diagnosed 150 (37) 126 (38) .84 
     Maintenance or disease-free 172 (42) 146 (44) .64 
     Recurrent or progressive 83 (20) 57 (17) .35 
 
Patients who screened positive for pain or for depression and expressed potential 
study interest in writing were contacted by telephone for an eligibility interview. The 
study was described in detail to those found to be eligible. Informed consent was 
audiotaped, with written consent obtained by follow-up mail. A baseline interview was 
completed after which the subject was randomized to either the intervention or usual care 
group.  
All assessments were administered by telephone interview. Table 3 presents an 
assessment timetable for the key constructs relevant to the current study, along with the 
instrument used, number of items, and, in appropriate cases, Cronbach’s coefficient 
alpha. Interviews were administered at baseline and at the end of month 1, 3, 6, and 12 
and include additional questionnaires not listed in the table because they are not relevant 
to the aims of the current study. To minimize patient burden, some measures, including 
those for fatigue, were not included in the 1- and 6-month interviews.  
Participants in both arms received $25 gift cards for each of 5 telephone research 
interviews. The oncology practice received $85 per enrolled patient for screening patients 
and providing medical record information for those enrolled. The current study analyzed 
data at baseline and 3 months. 
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Table 3  
Study instruments 
 Schedule 
Domain Measure Items 
Alph
a* 
0 
m
o 
1 
m
o 
3 
m
o 
6 
m
o 
12 
m
o 
Demographics age, race, sex, education, marital, job status, income  n/a X     
Medical comorbidity Checklist of 8 conditions 8 n/a X     
Depression 
• Patient Health 
Questionnaire (PHQ) 
• SCL-20 depression scale 
• SF-36 Mental Health 
Inventory Depression 
9 
 
20 
 
3 
0.81  
 
0.88 
 
0.77 
X 
 
X 
 
X 
 
 
X 
 
 
X 
 
X 
 
X 
 
 
X 
 
 
X 
 
X 
 
X 
Fatigue 
• SF-36Vitality scale 
 
 
 4 
 
 
0.76 
 
 
X 
 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
* Cronbach’s coefficient alpha at baseline for internal reliability of the scale; N = 405. 
 
 
 
INCPAD Eligibility 
To be eligible for the INCPAD study, cancer patients met study criteria for either 
pain or depression. Depression was required to be of at least moderate severity, 
operationalized as a PHQ-9 score of 10 or greater with endorsement of depressed mood 
and/or anhedonia. In past research, over 90% of patients meeting these criteria had major 
depression and/or dysthymia, and the depression of the remaining patients was clinically 
significant with substantial functional impairment (Kroenke, Spitzer, & Williams, 2001a; 
Kroenke, West et al., 2001). Patients were eligible to be enrolled for pain if they had a 
score of 5 or greater on the Brief Pain Inventory (Cleeland, 1991) suggesting moderate 
severity, provided that the pain had persisted after use of at least 2 different analgesics 
and was cancer-related (i.e., not a pre-existing pain condition unrelated to cancer). 
Individuals were excluded if they did not speak English, had moderately severe cognitive 
impairment as defined by a validated 6-item cognitive screener (Callahan, Unverzagt, 
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Hui, Perkins, & Hendrie, 2002), had schizophrenia or other psychosis, had a pending 
pain-related disability claim, were pregnant, or were in hospice care. 
During the 130-week enrollment period, 4,465 patients were screened in the 16 
participating clinics. Of those, 1,851 screened positive for pain and/or depression and 616 
were found to be eligible for the INCPAD trial (see flowchart, Figure 2). Of the 405 
participants enrolled, 131 (32.3%) had depression only, 96 (23.7%) pain only, and 178 
(43.9%) both depression and pain.  
 
 
 
 
 
 
 
Figure 2. INCPAD trial flowchart 
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Measures 
Vitality Scale of the SF-36. Fatigue was measured in the INCPAD study with the 
vitality scale of the SF-36 Health Survey, an instrument that assesses health-related 
quality of life (Ware, Snow, Kosinski, & Gandek, 1993). The 4 items of the vitality scale 
were each used as single-item indicators of the latent variable fatigue in the current study. 
The vitality scale was initially incorporated into the SF-36 to assess energy level and 
fatigue as a way to capture differences in subjective well-being. It asks respondents “How 
much of the time during the past 4 weeks “did you have a lot of energy?” “…have you 
felt full of life?” “…did you feel worn out?” and “…did you feel tired?” Respondents 
choose from a 5-level scale ranging from none of the time to all of the time.  
Standardized subscale scores range from 0 to 100, with higher scores indicating greater 
vitality. Norms for the vitality scale are based on a random general population sample of 
2,457 (Ware et al., 1993). When analyzing the vitality scale as a dichotomous measure, 
previous researchers have categorized scores above the midpoint of 50 as representing 
well-being and scores below 50 as indicating disability due to fatigue (Bower et al., 
2006). Moreover, the 25th percentile has been established in the literature as a clinically 
significant indicator of impairment; that is, those scoring below the 25th percentile (which 
was 45 for females in the U.S.). 
The SF-36 has well established internal consistency, reliability, content validity, 
construct validity, and criterion-related validity, having been tested in a variety of 
population samples (Wu & McSweeney, 2004). The median reliability across multiple 
published studies was reported to be at or above 0.80 (Ware, Gandek, & IQOLA Project 
Group, 1994). Cronbach’s coefficient alpha for the SF-36 is high across studies; in a 
validation study, it was greater than 0.85 (Brazier et al., 1992). In baseline data from the 
INCPAD study, Cronbach’s coefficient alpha for the vitality scale was 0.77. The SF 
vitality scale has been widely used to assess fatigue across a range of conditions. A recent 
review (O'Connor, 2004) surveyed the number of citations in medical and psychology 
databases for commonly used measures of energy and fatigue and found the SF-36 
vitality scale to be the most-cited, with 2,449 references. O’Connor found evidence to 
support the vitality scale’s validity as a measure of the frequency of monthly feelings of 
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energy and fatigue, although he noted that with only 4 items, the scale may be limited in 
adequately representing all the facets of fatigue.  
 
 
 
Convergent Validity 
Multidimensional measures of CRF are becoming more common, as was seen in 
the review of 61 studies presented in the background section, whereas the vitality scale 
has been considered either a unidimensional scale of general fatigue (Jean-Pierre et al., 
2007) or a bi-dimensional measure of energy and fatigue (O'Connor, 2004). To support 
the use of the vitality scale as a measure of fatigue in the cancer context, it was compared 
to a multidimensional instrument, the Fatigue Symptoms Inventory (FSI), which was 
developed specifically to assess fatigue in cancer patients. The FSI is a 13-item self-
report instrument designed to measure the intensity and duration of fatigue and its 
interference with quality of life in cancer patients (Hann, Denniston, & Baker, 2000). 
Participants use 11-point scales to rate the severity of their fatigue in the past week in 
terms of worst, least, and average fatigue as well as fatigue “right now.” Frequency is 
measured by number of days with fatigue in the past week (0-7 scale). Perceived 
interference is measured with 7 items on an 11-point scale assessing the degree to which 
fatigue in the past week is judged to interfere with general level of activity, ability to 
bathe and dress, normal work activity, ability to concentrate, relations with others, 
enjoyment of life, and mood. Convergent, divergent, and construct validity of the FSI has 
previously been established in samples of women undergoing treatment for breast cancer, 
women who had completed treatment for breast cancer, and women with no cancer 
history. Cronbach’s coefficient alpha reliability for all subscales was found to be above 
0.70. A mean score of ≥ 3 across the 3-item FSI severity composite has been established 
as the optimal cutoff for identifying clinically significant CRF (Donovan, Jacobsen, 
Small, Munster, & Andrykowski, 2008).  
In INCPAD, the FSI was administered to a subset of participants during 1-month 
(n = 68) and 6-month (n = 96) interviews. These participants represented a consecutive 
sample of individuals undergoing 1- and 6-month interviews during this secondary 
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validation study in INCPAD. Results of the three subscales of the FSI were compared to 
the SF vitality scores and a single item from the PHQ-15 Somatic Symptom Scale 
(Kroenke, Spitzer, & Williams, 2001b). The PHQ fatigue item asks respondents to rate 
how bothered they have been by “feeling tired or having low energy” over the past 4 
weeks. Response choices are “not bothered at all,” “bothered a little,” and “bothered a 
lot.” Correlations among the scales were examined and the scales’ effect sizes of change 
over 5 months were compared to evaluate sensitivity to patient-reported change.  
Internal consistency was excellent for the vitality scale (α = 0.91), and the FSI 
severity (α = 0.89) and interference (α = 0.91) subscales. Mean scores for both the FSI 
and the vitality scale demonstrated clinically significant fatigue in the subset sample, 
according to the established cutoffs of ≤ 45 for the vitality scale and ≥ 3 for the FSI 
severity composite (Table 4; Donovan et al., 2008). As expected, the vitality scale—with 
directionality that is the reverse of the FSI—was strongly inversely correlated with all 
three FSI scales. Moreover, both the FSI scores and the vitality score correlated strongly 
with the PHQ fatigue item in the expected directions, with the vitality scale having the 
strongest correlation (see Table 5). 
To compare the scales’ sensitivity to change, standardized response means (SRMs) 
were calculated for each fatigue scale, a method that has been used in previous studies  
 
Table 4 
Change Scores and Standardized Response Means (N = 58) 
Fatigue measure 
 
Range * 1-month  
Mean (SD) 
6- month 
Mean (SD) 
Change score  
Mean (SD) † 
SRM 
‡ 
SF Vitality 0-100 35.7  (21.5) 34.1  (23.1) -1.62 (20.2) -0.08 
FSI Severity 0-10 5.48  (2.07) 4.98  (2.21) -0.50 (2.40)  0.21 
FSI Interference 0-10 4.70  (2.37) 3.86  (2.50) -0.84 (2.19) -0.38 
FSI Duration 0-7 3.46  (2.09) 3.28  (2.14) -0.18 (2.33) -0.08 
PHQ Fatigue Item 0-3 2.07  (0.92) 2.07  (0.93) 0.0 (1.14)  0.0 
 
* Bolded number represents worst score 
†  Change score = 6 month score – 1 month score 
• For all FSI scales and PHQ fatigue item, higher scores indicate worse fatigue and 
negative change scores indicate improvement.  
• ‡  Standardized response mean (SRM) = mean change score/SD of change scores 
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Table 5 
Correlation Matrix at 1 Month (n = 68) and 6 Months (N = 96) 
Fatigue Scale 
  -- 1 month 
  -- 6 months 
SF 
Vitality 
FSI 
Severity 
FSI 
Interfere 
FSI 
Duration 
PHQ 
Fatigue 
Vitality Scale 
  
-.70 
-.68 
-.77 
-.71 
-.75 
-.71 
-.78 
-.75 
 
FSI Severity 
 
  .83 .78 
.70 
.74 
.67 
.62 
FSI Interference    .81 .79 
.72 
.65 
 
FSI Duration 
 
    .74 .70 
PHQ Fatigue  
      
 
(Krebs et al., 2009; Löwe, Kroenke, Herzog, & Gräfe, 2004). Mean change scores were 
derived by subtracting the 1-month mean score from the 6-month mean score; then this  
value was divided by the standard deviation of the change score. Frequency distributions 
of the SRMs were similar and approximated a bell shape for each fatigue measure, albeit 
with a positive skew (Figure 3).  
The findings from this measurement validation analysis support the use of the 
vitality scale to measure fatigue in the INCPAD cancer sample for the main analysis. The 
vitality scale performed similarly to a longer multidimensional scale (i.e., the FSI) that 
was developed specifically to assess cancer-related fatigue and validated in multiple 
cancer samples. The vitality scale’s strong correlation with both the FSI and with the 
PHQ-15 fatigue item support its construct validity. Moreover, it demonstrated sensitivity 
to longitudinal change that was similar to that of the FSI. 
Depression Subscale (SCL-20) of the Hopkins Symptom Checklist (SCL-90). The 
SCL-20 was the primary outcome measure for depression in the INCPAD study and one 
of three depression scales used in the current study. The SCL-20 is a modified subscale of 
the SCL-90 that was chosen for its demonstrated sensitivity in detecting differences in 
depression severity between treatment groups in previous trials (Kroenke, West et al., 
2001; Unutzer et al., 2002). The 20 items ask respondents to rate how much distress was 
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Figure 3. Comparison of change scores (standardized response means; SRMs) of the SF-
36 vitality scale and the severity and interference subscales of the FSI at 1-month and 6-
month assessment. (SRMs = mean change score/SD of change scores.)  
 
 
experienced over the past 4 weeks because of various symptoms such as “feeling lonely 
or blue,” “feeling no interest in things,” “trouble falling asleep,” and “thinking, speaking, 
and moving at a slower pace.” For each item, five response choices range from “not at 
all” to “extremely.” 
The SCL-20 is well validated. In several studies of varied patient populations, 
correlations between the depression subscale of the SCL-90-R and the Beck Depression 
Inventory ranged from 0.73 to 0.80. The diagnostic utility of the SCL-90-R has also been 
demonstrated in several studies (Derogatis, 1994). In INCPAD, Cronbach’s coefficient 
alpha was 0.89.  
Patient Health Questionnaire, Depression (PHQ-9). The PHQ-9 is the depression 
module of the full Patient Health Questionnaire, a self-administered diagnostic 
instrument for common mental disorders developed for use in primary care settings 
(Kroenke, Spitzer et al., 2001a). Its nine depression items comprise the nine criteria upon 
which the diagnosis of depressive orders is based (Diagnostic and Statistical Manual of 
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Mental Disorders, 4th Edition Text Revision, 2000). In 2 studies including 6,000 patients, 
the PHQ-9 performed well as a brief measure of depression severity and showed good 
construct and criterion validity (Kroenke, Spitzer et al., 2001a). It has been recognized as 
a dual-purpose instrument for making diagnoses and assessing severity. 
When administering the PHQ-9, interviewers ask respondents whether they have 
been bothered by a specified symptom over the last 2 weeks. Examples of symptoms are 
“little interest or pleasure in doing things,” and “feeling bad about yourself, feeling that 
you are a failure, or feeling that you have let yourself or your family down.” If the 
response is yes, then participants are asked whether they were bothered “several days,” 
“more than half the days.” or “nearly every day.” Cronbach’s coefficient alpha for the 
PHQ-9 in the INCPAD sample is 0.81. 
Mental Health Inventory (MHI-3). The MHI-3 is a depression subscale of the 
Mental Health Inventory-5, which in turn is part of the SF-36 Health Survey. The MHI-3 
recently has been validated as a measure for depression (Cuijpers, Smits, Donker, ten 
Have, & de Graeff, 2009; Rumpf, Meyer, Hapke, & John, 2001; Yamazaki, Fukuhara, & 
Green, 2005). The MHI-5 consists of 5 items from the SF-36 and assesses mental health 
(Rumpf et al., 2001). It has been tested in a large sample of the general population (n = 
4,036) for its ability to screen for various mental disorders, especially depression and 
anxiety. It performed best in detecting depressive disorders, with sensitivity and 
specificity statistics comparable to 9 lengthier instruments used in primary care. More 
recently, Cuijpers and colleagues (2009) undertook ROC analysis and found no 
difference between the MHI-5 and the MHI-3 in detecting major depression and 
dysthymia. The MHI-3 items ask “How much of the time during the last month have you: 
1.) felt downhearted and depressed?, 2.) been happy? and 3.) felt so down in the dumps 
that nothing could cheer you up?” Respondents choose from 5 options ranging from 
“none of the time” to “all of the time.” Cronbach’s alpha for the MHI-3 in the INCPAD 
sample was 0.77.  
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Analysis 
Cross-lagged panel analysis, a structural equation modeling technique, was used 
to test the hypotheses. As a way of ameliorating measurement error—a common threat to 
validity in causal analysis—a latent variable approach was used (Shadish, Cook, & 
Campbell, 2002). Panel data consists of at least two variables measured at two or more 
time-points in the same set of subjects. Analysis of panel data has been recognized for its 
advantages in testing for causal effects because it can provide evidence regarding all 
three conditions of causality: 1) covariation of the 2 variables; 2) time precedence of the 
causal variable; 3) and nonspuriousness (i.e., the association of the 2 variables must not 
be produced by a joint association with a third variable or set of variables) (Finkel, 1995). 
A cross-lagged model is also a basic approach for estimating possible reciprocal effects. 
It provides the means to address the question: “Which is the more important influence, 
depression (D) on fatigue (F), or fatigue on depression?” (Greenberg, 2008). 
Figure 4 illustrates the model for the main analysis. It incorporates a linear 
structural equation for a continuous dependent variable fatigue (F) at 3 months (T2). The 
equation included depression (D) at baseline (T1) and T2, and F at T1. The intervention 
group assignment was entered into the equation as a control variable.  
The model comprises two portions—measurement and structural. The 
measurement model is made up of the observed variables (boxes in the model), which 
serve as indicators for the latent, or unobserved, variables (circles in the model). 
Unidirectional arrows from the latent variables to the indicators represent factor loadings. 
The structural model includes the latent variables and specifies the hypothesized pattern 
of causal influence. Straight unidirectional arrows between latent variables represent 
specified causal pathways, and two-headed arrows represent covariance (unanalyzed in 
the case of exogenous variables), or in the standardized solution, correlations. Error 
terms, also called disturbances, are represented by arrows coming into the variables from 
an unmodeled source.  
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Figure 4.  Latent variable cross-lagged panel model of the relationship of depression and 
cancer-related fatigue. 
 
 
 
Measurement Model 
Specification of the indicators for the latent variables fatigue and depression was 
carefully considered so as to minimize the potential for measurement error. For 
depression, instrument sum scores were used as indicators, whereas for fatigue, 
individual items serve as the indicators. Little, Cunningham, Shahar, and Widaman 
(2002) extolled the utility of using intact scales with established norms and psychometric 
properties as indicators of a latent construct. Their endorsement of entering scores from 
such scales in their original untransformed metric provided the basis for the specification 
of the depression measurement model, as the validity of all three instruments used in the 
INCPAD study for measuring depression has been empirically established. The use of 
three indicators can be considered a strength, as it renders the latent construct of 
depression as locally “just-identified.” This means that the number of parameters and 
observations is equal (Kline, 2005) and therefore a single unique solution exists that 
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optimally captures the relations among the items. Little and colleagues (2002) argue that 
just-identification is ideal for the measurement of a latent construct in a structural 
equation model. 
For fatigue indicators, items were considered individually rather than at the scale-
total level primarily because the INCPAD study included only one fatigue scale, as the 
study was not designed with fatigue as an intended primary outcome. Aside from fatigue 
items embedded in the depression instruments, available fatigue-related items in the 
INCPAD questionnaire included the four that make up the vitality scale and a single item 
from the PHQ-15 Somatic Symptom Scale discussed in the Measures section. The latter 
was ruled out as an indicator because data seriously violated the normality assumption of 
SEM. Responses were on a 3-point scale, and at baseline, 319 respondents (79%) 
endorsed the choice representing the most bother from fatigue, making for a highly 
negatively skewed distribution. With only the vitality scale remaining, use of the total 
score as a single indicator would be less than ideal, as multiple measures of a latent 
construct reduce the effects of measurement error (Kline, 2005). Thus, the 4 items of the 
vitality scale were used as indicators for fatigue. 
 
 
 
Structural Model 
The model was specified according to convention in cross-lagged panel data 
(Finkel, 1995; Greenberg, 2008; Kessler & Greenberg, 1981; Shadish et al., 2002). The 
structural pathways between F1 and F2 (fatigue) and between D1 and D2 (depression) 
serve to adjust each 3-month variable for its corresponding baseline level; therefore the 3-
month variables represent residualized change scores. A significant correlation for the 
pathway (b12) from D1 to F2 would lend support to hypothesis 1. A significant 
correlation for pathway (b21) from F1 to D2 would lend support for hypothesis 2 
provided that the magnitude is lower than for b12. The INCPAD intervention group 
assignment is modeled as a single-indicator latent variable in the model. 
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Statistical Analysis 
The analysis was conducted with maximum likelihood estimation using LISREL 
8.8 (Jöreskog & Sörbom, 2008). Evaluation of the hypothesized model fit included a 
measurement phase and a structural phase. In SEM, a variance-covariance matrix is 
generated from observed data. Factor analysis is used to confirm the measurement model 
that defines the latent variables. The structural phase involves a path-analysis approach, 
in which the SEM program determines estimates that will most nearly reproduce the 
variance-covariance matrix. The program finds estimates for each parameter that are most 
likely to reproduce the observed path beta coefficients while simultaneously taking into 
account the most likely possible reproduction of all the other correlations in the input 
matrix. Kline’s (2005) outline of steps for completing an SEM analysis guided both 
stages of the analysis, including detailed data preparation and screening. Major steps 
included evaluating model fit, interpreting the parameter estimates, and considering 
equivalent models. In SEM, if the initial structural model does not fit the data well, it 
may be re-specified and re-evaluated before continuing with the interpretation of 
estimates. 
SEM program output includes various fit indices that allow the investigator to 
statistically assess whether and how well the observed model fit the hypothesized model 
(Klem, 2000). For the current study, fit indices selected a priori to determine goodness-
of-fit included indices of absolute fit, the chi-square statistic (χ2) and the Standardized 
Root Mean Squared Residual (SRMR); a parsimonious fit index, the Root Mean Square 
Error of Approximation (RMSEA); and an incremental fit index, the Comparative Fit 
Index (CFI) (Hu & Bentler, 1999; Weston, Gore, Chan, & Catalano, 2008). Guidelines 
for interpreting the indices and cutoff scores for the current study are at Table 6. 
 
 
 
Power Analysis 
SEM is generally understood among statisticians to require large samples, with 
200 being the suggested minimum threshold (Barrett, 2007; Kline, 2005). Increasingly 
complex models require larger samples, and certain estimation methods require very  
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Table 6 
 
Fit Indices and Cutoffs for the Current Study 
 
Index (Range) Guidelines for interpretation Cutoff  
Chi Square (χ2) Nonsignificant χ2 suggests the model fits 
the data (i.e., differences non-significant). 
Usually significant in larger samples. 
 
> 0.05 
 
Standardized Root Mean 
Square Residual (SRMR;   
0 - ∞) 
0 = perfect fit. Values lower than 0.06 
indicate good fit 
 
< 0.06 
Root Mean Square Error of 
Approximation 
(RMSEA; 0 - ∞) 
 
0 = perfect fit; suggested cutoff is 0.05 < 0.05 
Comparative Fit Index  
(CFI; 0 - 1) 
Values closer to 1 indicate better fitting 
model; suggested cutoff is 0.95 
> 0.95 
 
Sources: Hu & Bentler (1999); Weston, Gore, Chan, and Catalano (2008) 
 
 
large numbers. For path analysis, Kline made a general recommendation to have a ratio 
of participants to free parameters at 20:1, although he allowed that 10:1 may be a more 
realistic target. If the ratio falls below 5:1, the statistical analysis is in doubt, according to 
Kline’s rules of thumb. The hypothesized path model for the proposed study has 37 
parameters to be estimated; therefore it requires 185 cases to be considered viable 
according to these guidelines. The main analysis was ultimately run only with cases with 
no missing data, leaving a sample size of 329, which fell short of the recommended 
numbers but well exceeds the lower threshold of acceptability. 
Alpha was set at .05, 2-tailed. Kline (2005) noted that statistical significance 
testing is less central in SEM than in many conventional data analysis techniques, partly 
because of the difficulty securing large enough sample sizes to detect significant effects. 
More than that, however, in SEM the focus tends to be on the evaluation of entire models 
and the fit statistics, with the big-picture view taking precedence over attention to 
individual effects. 
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RESULTS 
 
 
 
The data were screened relative to the assumptions of SEM procedures (Kline, 
2005; Tabachnick & Fidell, 2000) using SPSS (PASW) 17 statistical software. For each 
variable of the main model, range values, means, and standard deviations (SDs) were 
inspected for plausibility. Univariate outliers were identified through box plots and 
examined. Two cases that were more than 3.5 SDs beyond the mean on the SF energy 
variable were adjusted to 0.5 above the next highest value, thus keeping the scores in the 
analysis but reducing the potential for distortion of the distribution. Scatter plots for the 
depression scales were examined for multivariate outliers as a way of confirming 
assumptions of linearity and homoscedasticity. An examination of a single extreme case 
revealed it to have a low baseline PHQ-9 score while the other depression scales were 
very high, along with other incongruities in the data. The score for the baseline PHQ-9 
was deleted for that case. Mahalanobis distance statistics were reviewed in search of 
multivariate outliers. As a result, three cases were examined for incongruity among the 
scores but none were found to be extreme. No adjustments were made based on the 
Mahalanobis distance statistics. Each distribution was evaluated for normality by 
examining histograms and statistics for skewness and kurtosis. Depression scales 
consistently approximated a normal distribution. The vitality scale item distributions 
roughly resembled normal but were positively skewed. None had skewness or kurtosis 
values exceeding the absolute value of 1, however, suggesting each was within the range 
of a normal distribution (Mertler & Vannatta, 2005). The conclusion of this assessment 
was that deviations from normality were insubstantial so that standard SEM analysis and 
fit indices were used. The assumption of multicollinearity was checked by reviewing the 
squared multiple correlations between each key variable and the others, reported in the 
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LISREL output. In no case did the statistic exceed 0.90, which is the cutoff suggested by 
Kline (2005). 
The sample size was reduced to 329 for the main analysis because the SEM 
procedure would not converge using the full dataset (N = 405). The problem was 
resolved by using only cases with full data, an approach recommended by Kenny and 
Harackiewicz (1979) for cross-lagged panel analysis. Cases that were not assessed at 3 
months (17% of the sample) accounted for a large proportion of the missing data. At the 
time their 3-month assessment was due, 16 participants had died, 24 had dropped out, and 
the research team was unable to make contact with 30 (see flowchart, Figure 2). Baseline 
characteristics of the 329 participants who were included in the current analysis were 
compared to those of the full INCPAD sample using T-tests or Z-tests for proportions. 
No significant differences were found between the groups for age, gender, race, 
education, marital or employment status, income, type or phase of cancer, number of 
comorbid diseases, disability, or mean scores for fatigue, pain, depression, or quality of 
life (see Table 2). 
Bivariate correlations, means, and SDs are presented for the fatigue measures and 
separately for the depression measures in Table 7. A table with correlations across all 
variables at both time-points can be found at Appendix C. Magnitudes in the latter table 
ranged from 0.24 to 0.85. All correlations were significant and in the expected direction. 
Values between fatigue and depression were negative; however, this suggested a positive 
association as expected because higher vitality scores suggest less fatigue whereas higher 
depression scores suggest worse symptoms. Visual inspection revealed that 
intercorrelations among the depression scales tended to be higher than those among the 
fatigue items. At baseline, depression scale correlations ranged from 0.65 to 0.74 and at 3 
months from 0.73 to .85. For fatigue, baseline correlations ranged from 0.29 to 0.74 and 
at 3 months from 0.45 to 0.78, with the strongest association being between the two items 
referring to feeling tired and feeling worn out.  
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Table 7  
 
Bivariate Correlations, Means, and SDs for Fatigue and Depression 
 
Fatigue 
 
Variable 1 2 3 4 M SD 
1. SF energy — .41 .48 .49 1.90 0.88 
2. SF life .53 — .29 .35 2.40 1.15 
3. SF worn .53 .49 — .74 2.29 1.06 
4. SF tire .56 .45 .78 — 2.06 0.99 
M 2.19 2.58 2.65 2.44   
SD 1.03 1.22 1.13 1.08   
 
Depression 
 
Variable 1 2 3 M SD 
1. PHQ-9 — .74 .65 12.84 6.85 
2. SCL-20 .85 — .74 1.44 0.73 
3. MHI-3 .73 .76 — 8.05 2.96 
M 9.20 1.10 7.26   
SD 6.28 0.69 3.02   
 
Note. N = 329. Intercorrelations for Time 1 are presented above the diagonal, and 
intercorrelations for Time 2 are presented below the diagonal. Means and SDs for Time 1 
are presented in the vertical columns, and means and SDs for Time 2 are presented in the 
horizontal rows. For fatigue measures, higher scores indicate greater vitality. For 
depression scales, higher scores indicate more depression. From the SF vitality scale: SF 
energy = “How much of the time during the past 4 weeks…did you have a lot of 
energy?” SF life = “…have you felt full of life?” SF worn = “…did you feel worn out?” 
SF tire = “…did you feel tired?” PHQ-9 = Patient Health Questionnaire, Depression, 
SCL-20 = Depression Subscale of the Hopkins Symptom Checklist, MHI-3 = Mental 
Health Inventory Depression Subscale. 
All correlations are significant at the 0.01 level (2-tailed). 
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As for the cross-sectional correlation of fatigue with depression, the total for the SF 
vitality scale score at baseline was found to have relatively strong and significant 
correlations with all three depression scales. For the PHQ-9, r = -0.49, for the SCL-20, r 
= -0.62, and for the MHI-3, r = -0.54, with negative correlations indicating that greater 
depression was associated with less vitality/greater fatigue. 
 
 
 
Measurement of Fatigue and Depression 
Prior to testing the causal model, the measurement model was examined through a 
confirmatory factor analysis (CFA) to increase confidence that the specified indicators 
for depression and fatigue were indeed capturing separate constructs in the sample data. 
First, the model was tested using baseline data with latent factors of fatigue and 
depression each being assigned the respective indicators, and with the latent factors being 
allowed to correlate freely. The standardized correlation of fatigue and depression was 
0.76. Factor loadings were consistently strong (range of standardized estimated 
correlations for fatigue indicators was -0.58 to -0.69; for depression indicators, 0.78 to 
0.94) and all model indices suggested good fit χ2 (11, N = 329) = 17.72 (p = 0.08), 
SRMR = 0.031, RMSEA = 0.043, and CFI = 1.00. To further confirm the existence of 
two factors, a second model was analyzed for comparison in which the correlation 
between the latent factors was fixed to equal 1.0, thereby rendering the two factors as 
identical—essentially equivalent to replacing the two factors with one (Kline, 2005). 
Relative fit of the two models was tested with the chi-square difference test. The fit of 
two models was found to differ significantly, χ2 (1, N = 329) = 54.37 (p < .005) with the 
two-factor model having superior fit. The tests were repeated with 3-month data with a 
similar outcome. Results suggested that the indicators selected for the causal analysis 
were capturing two distinct factors in the data as intended. 
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Structural Analysis of Panel Data 
The aim of the current study was to examine whether depression exerts causal 
influence on fatigue over time in cancer patients and whether reciprocal effects exist. 
Both hypotheses—that depression would predict changes in fatigue over 3 months and 
that reciprocal effects would exist but would be of lower magnitude—were evaluated in 
the same analysis of panel data. The model was specified as has already been presented in 
Figure 4.  
In an effort to avoid error due to omitted predictors, several variables were tested 
as potential control variables. Age, gender, cancer type, and cancer phase were evaluated 
as potential confounders, along with other variables that have been found in previous 
research to be associated with CRF. Baseline bivariate correlations for cancer type, 
cancer phase, anxiety, pain, sleep quality, shortness of breath, and activity were 
reviewed—some of which were measured in the INCPAD study with standardized scales 
and others of which were measured with one or two items. The range of magnitude of 
correlations with fatigue was 0.02 to 0.36; the range of magnitude of correlation with 
depression was 0.04 to 0.43. Although some of the baseline bivariate correlations were 
relatively small in magnitude, each variable had a statistically significant correlation 
either with fatigue items or depression scales or both. Tests were run to see if including 
each baseline variable in the model would have a significant effect on fatigue or 
depression at the second time-point. No significant effects were found; therefore, no 
control variables were included in the main analysis except the intervention arm, which 
had been included in the hypothesized model. 
The initial analysis with the a priori model specified as planned (Figure 4) did not 
show adequate fit, χ2 (76, N = 329) = 279.21, (p < 0.001), SRMR = 0.073, RMSEA = 
0.09, and CFI = 0.97. Examination of the Lagrange multiplier modification indices, 
however, suggested that allowing the “full of life” fatigue indicator to cross-load on 
depression at each time point would reduce χ2 , thereby improving fit. This item from the 
SF vitality scale asks “How much of the time during the past 4 weeks have you felt full of 
life?” Because it is conceptually plausible that this item would provide information 
relevant to both depression and fatigue (see further discussion later), a new model was 
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created with parameters freed from latent depression to the sflife indicator at each time 
point. Eight correlations between error terms were also freed based on modification 
indices, after determining the conceptual reasonableness of each change. Parameters were 
freed to allow item error terms to correlate between “tired” and “wornout” items and 
between “full of life” and “a lot of energy” at each time point. Further, the “full of life” 
error terms were allowed to correlate with the MHI-3 error terms.  
The revised model achieved good fit, as demonstrated by three of the four fit 
indices selected a priori: χ2  (66, N = 329) = 88.16, p = 0.04, SRMR = 0.030, RMSEA = 
0.032, and CFI = 1. Although the significance of χ2 suggests the data failed an absolute-
fit test, this finding is expected since an exact fit is a rare occurrence, especially in larger 
samples (Weston et al., 2008). Kline (2005) advised that over-reliance on χ2 as a fit index 
may lead to rejection of models with reasonably good fit.  
Because the new measurement model fit the data well, it was used for the causal 
analysis. Although statistically suggested modifications were made post hoc—a 
procedure that has been challenged by some in the SEM literature (Kline, 2005; Weston 
et al., 2008)—the changes were conceptually reasonable and were deemed to be minor 
relative to the overall model structure. 
The main findings are presented in Figure 5. The cross-lagged structural path 
from baseline depression to fatigue at 3 months was nonsignificant (standardized β = 
0.01, z = 0.10) suggesting that baseline depression had no causal influence on change in 
fatigue after 3 months. Likewise, the structural path from baseline fatigue to depression at 
3 months was nonsignificant (standardized β = 0.10, z = 1.07). Neither of the study 
hypotheses was supported by these results. Results for the structural paths from the 
intervention group control variable lent additional support for the validity of the model. A 
significant positive effect was found on change in depression at 3 months for membership 
in the intervention arm of the study (standardized β = 0.20, z = 4.35), showing that the 
depression intervention predicted less depression at Time 2. No effect of the intervention 
was found for fatigue, however, as the structural path from the intervention control 
variable to fatigue was nonsignficant (standardized β = 0.09, z = 1.61). 
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Figure 5. INCPAD cross-lagged panel model. *Shaded indicator (sflife) is a crossloading 
item. Values for unidirectional arrows (structural paths) are standardized regression 
coefficients; values associated with bidirectional arrows are Pearson correlation 
coefficients. Paths with significant coefficients are solid; nonsignificant paths are dashed. 
Shading indicates a control variable (i.e., Intervention Group). Loadings of fatigue 
indicators are negative because higher observed scores suggest lower fatigue (sftired and 
sfwornout scores were reversed).  p < 0.05. 
 
 
A critical structural assumption that must be met in order for a cross-lagged panel 
analysis to be valid as a test of causal influence is that of stationarity, the requirement that 
the correlations between fatigue and depression are equal at both time points (Kenny & 
Harackiewicz, 1979). To set conditions conducive to stationarity, the variables to be 
tested in cross-lagged analysis should be correlated at a moderate to large magnitude—at  
least 0.30. In the current main analysis, the unstandardized correlation of fatigue with 
depression was 0.71 at time 1 and 0.78 at time 2. In order to insure the difference was 
nonsignificant, an alternate model was created with the correlations between the 
synchronous latent variables constrained to be equal. The fit indices of this model were 
then compared to the main model, which had no such constraint. The indices were nearly 
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identical. Indices for the constrained model were χ2 (66, N = 329) = 88.72, p = 0.04, 
SRMR = 0.03, RMSEA = 0.03, and CFI = 1.00. A χ2 difference test was nonsignificant, 
Δχ2 (1,0, N = 329)
 = 0.56, p = 0.45, indicating that the models were not significantly different; 
thus the assumption of stationarity was met. 
An alternative model was evaluated to explore the consequences of reducing 
obvious measurement overlap between fatigue and depression. Because fatigue is a core 
symptom of depressive disorders, measurement overlap exists in many multi-item self-
report depression scales (Brown & Kroenke, 2009; Jacobsen et al., 2003). As has already 
been mentioned, previous researchers seeking to understand the relationships between the 
two symptoms have attempted to address this either by choosing depression instruments 
that focus exclusively on mood symptoms or by comparing relationships of the two 
constructs with and without fatigue-related items included in multidimensional 
depression scales. Two of the depression indicators in the current study contain items 
assessing fatigue symptoms. The SCL-20 asks how much distress had been caused by 
“feeling low in energy or slowed down” and “feeling everything is an effort.” The PHQ-9 
asks about being bothered by “feeling tired or having little energy.” An alternative dataset 
was prepared with these items dropped from the depression scales. The model was then 
estimated the same as in the main analysis but with the revised dataset.  
Again, model indices suggested a good fit, and unlike the main model, the chi-
square statistic was nonsignificant, suggesting it met the specifications for absolute fit, χ2 
(66, N = 329) = 81.67, p = 0.09, SRMR = 0.027, RMSEA = 0.044, and CFI = 1.00. The 
cross-lagged paths between fatigue and depression remained nonsignificant, suggesting 
no causal influence—consistent with the main analysis. The magnitudes of most of the 
structural paths in the model changed, although none by more than 0.10, as follows: D1 
 D2 standardized β = 0.56; F1  F2 standardized β = 0.69; D1  F2, standardized β = 
-0.02, ns; F1  D2, standardized β = -0.08, ns. Correlations between the latent variables 
at baseline were different from the main model results (-0.67 compared to -0.71 with 
complete measures) and again at three months (-0.39 compared to -0.42). The magnitude 
of effects of the intervention control remained the same. Although analyzing the model 
with an apparent reduction in measurement overlap did appear to improve the fit of the 
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model somewhat, statistical comparison could not be undertaken because the models are 
not nested. The structural effects did not change in any apparently meaningful way. This 
outcome suggests the overlap of fatigue items in the depression scales did not unduly 
influence the findings. 
  
51 
 
 
 
 
 
DISCUSSION 
 
 
 
The purpose of the current study was to examine whether causal influences exist 
in the relationships between depression and fatigue in cancer patients. Based upon a 
theory that depression is a perpetuating factor of CRF, the main hypothesis held that 
depression would have causal influence on fatigue over time. A second hypothesis held 
that a reciprocal effect would be found, but that the influence of depression on changes in 
fatigue would be stronger than the reverse. The sample comprised 329 patients with 
various types of cancer and in different phases of oncology treatment or post-treatment 
who participated in a 12-month RCT of an intervention to treat depression and pain 
symptoms. Data from baseline and 3 months were analyzed for fit with a cross-lagged 
panel model, a statistical method that has been endorsed in the literature as an appropriate 
method to assess for directional causal influence. Results failed to support either of the 
study hypotheses. The data fit the model reasonably well; however, no evidence was 
found to support the hypothesis that depression had a causal influence on fatigue over 
three months during the course of the intervention. Furthermore, no support was found in 
this analysis for the hypothesis that fatigue causally influences depression over time.  
The findings are supported by several strengths in study design. The fact that the 
majority of the sample entered the study with both elevated depression and fatigue 
assured appropriate range to demonstrate improvement over time. Moreover, conducting 
this analysis in a trial of a treatment that targeted depression increased the likelihood that 
depression would improve within the 3-month timeframe, a condition that is ideal for an 
evaluation of causal influence of this nature. The findings replicated those of the 
INCPAD trial suggesting that the depression-and-pain intervention had positive effects 
for depression compared to the usual care control group. Fatigue, however, was not 
significantly affected by intervention group membership, according to the panel analysis. 
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The sample of 329 was sufficient to support the analysis. Measurement was found to be 
adequate in the confirmatory factor analysis step. That taken together with the fact that 
latent variable SEM accounts for measurement error suggests that the validity of these 
findings may be less threatened by measurement error than are many studies using other 
statistical approaches. 
These findings make an important contribution to what is currently understood 
about the interrelationship of depression and CRF. Although a strong correlation between 
depression and CRF has been well established in previous research, far too few 
longitudinal studies have been undertaken and little is known about causal influences. 
Only a few studies have attempted to evaluate whether these symptoms tend to change 
together or independently over time, and the results have been mixed and inconclusive. A 
comprehensive search of the literature revealed none that had employed structural 
equation modeling, an advanced technique in causal analysis. 
Although the number of studies that have analyzed the causal relationship 
between CRF and depression are few and results are mixed, the current findings are 
consistent with the majority of the published longitudinal studies in this domain. Perhaps 
the one with the most notable similarities in findings is a randomized, double-blind 
controlled trial of paroxetine to treat fatigue in patients (N = 479) undergoing 
chemotherapy for the first time (Morrow et al., 2003). As in the current study, 
participants with a variety of types of cancer were recruited from multiple oncology sites 
and pharmacological treatments were featured. A key difference is that in the Morrow 
and colleagues trial, fatigue was the symptom that was targeted, whereas the INCPAD 
trial targeted depression and pain. Another important distinction is found in the way the 
hypotheses were conceptualized, as the study by Morrow and colleagues tested whether 
the two symptoms share a common etiology. Instead of conceptualizing depression as a 
perpetuating factor, Morrow and colleagues had hypothesized that fatigue and depression 
share a common neural pathway involving serotonin. However, they found that 
paroxetine, a selective serotonin reuptake inhibitor, reduced symptoms of depression 
within 3 weeks but had no effect on fatigue at either of two follow-up assessments at 
cycles 3 and 4 of chemotherapy. As in the current study, these investigators found that 
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although depression and fatigue were strongly correlated in the sample, only depression 
was affected by the intervention. 
The current findings are also consistent with those of Visser and Smets (1998), 
who studied fatigue, depression, and QoL by interviewing a heterogeneous sample of 250 
cancer patients a week before beginning radiation therapy, 2 weeks after treatment, and 9 
months later. One of the stated aims of their study was to investigate the cause-and-effect 
relation between fatigue and depression. Because correlations have been found to be so 
high, investigators expected fatigue and depressive mood to follow a similar course over 
time, but instead each exhibited independent patterns of change. In four other studies that 
used smaller samples of patients with specific cancer types currently receiving treatment, 
researchers reported findings about the longitudinal relations of fatigue and depression 
that could be interpreted to suggest that the two symptoms change (or fail to change) 
independently over time (Geinitz et al., 2001; Pirl, 2008; Schumacher et al., 2002; Stone, 
Hardy et al., 2000).  
One of these groups of investigators, Stone and colleagues, reported findings from 
a different study that could be taken to suggest that the two symptoms may tend to 
change together. They evaluated depression, fatigue, and other symptoms occurring as 
treatment-emergent side effects in breast or prostate cancer patients (N = 69) who were 
assessed before and after radiation therapy (Stone et al., 2001). In their study, small but 
significant increases in depression scores were associated with small increases in fatigue 
scores. This research differed from the current one in that it focused on fatigue increases 
relating to radiation therapy and there was no treatment for either depression or fatigue 
involved.  It is plausible that a cytotoxic treatment such as radiation therapy can have 
several side effects that differ in etiology, in which case the simultaneous increases in 
both fatigue and depression were not causally related but due to different mechanisms. 
Only one other study (N = 250) reported finding a longitudinal relationship in 
change in depression and fatigue (Tchekmedyian et al., 2003). This was a secondary 
analysis of data from a randomized, double-blind, placebo-controlled trial of darbepoetin 
alfa to treat anemia in lung cancer patients. The study was conceived as a test of whether 
improvements in fatigue would predict improvements in the distress of depression and 
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anxiety. Assessment of fatigue, anxiety, and depression occurred at baseline and between 
weeks 4 and 12. Improvements in fatigue were associated with reductions in both 
depression and anxiety. In multiple regression, for each unit of improvement in the 
fatigue score, there was a corresponding improvement of 0.7 units in anxiety and 0.8 
units in depression levels. Although the Tchekmedyian and colleagues study findings 
suggest a causal influence between fatigue and depression, there are differences in design 
from the current study that are important. It is possible that the fatigue associated with 
anemia is different from non-anemic CRF. For one thing, anemia has been established as 
a “treatable contributing factor” of CRF and has a pharmacologic treatment that is known 
to be helpful (Berger et al., 2009). The Tchekmedyian study sample was made up of lung 
cancer patients with anemia (hemoglobin ≤ 11 g/dL) and receiving cyclic platinum-
containing chemotherapy. In the current study, only 18% of participants were lung cancer 
patients and 44% were in maintenance or disease-free status. Anemia was neither 
assessed nor treated. These differences may account for the differences in findings of the 
current study and the previous study.  
Overall, in terms of the few relevant longitudinal studies that have been found in 
the literature, none directly contradicted the current study. Six of the longitudinal studies 
failed to support a causal influence between depression and fatigue in either direction; 
only two found a relationship between change in fatigue and change in depression and 
both were substantially different from the current study both in aims and design. 
 
 
 
Implications 
 
 
 
Theory 
The current study adds new data to the evidence regarding the three unanswered 
questions about CRF that were posed by Jacobsen et al. (2003) and discussed in the 
background (p. 14): first, to what degree do fatigue and depression conceptually differ; 
second, to what degree to they co-occur; and, third, are there causal relationships? 
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Regarding the first question, the current findings—both the measurement model and the 
structural model—are consistent with the theory that depression and fatigue are two 
distinct entities in the cancer context. This matter may have been previously settled 
(Skapanakis, Lewis, & Mavreas, 2004; Visser & Smets, 1998), but the high correlations 
of fatigue and depression and their overlap in multidimensional measurement and 
syndrome-based diagnoses continue to blur the boundaries between the two symptoms. 
Reuter and Härter (2004), for example, published a conceptual paper positing that when 
accompanied by a depressive disorder in cancer, fatigue is subsumed by the depression 
symptom complex. They concluded that the question of diagnostic independence remains 
unanswered and expressed the hope that certain antidepressant medications might help 
with CRF. One could point to the cross-loading of one of the SF vitality scale items in the 
current study—the “full of life” item—as an example of a blurring of the distinction. This 
item has been validated to measure respondents’ status on an energy/fatigue continuum. 
In our measurement model, SF life loaded adequately on the latent fatigue variable. In the 
full panel model, however, the indicator statistically cross-loaded onto the latent variable 
for depression. Developers of the SF-36 have written about the difficulties they 
experienced in developing a scale for energy/fatigue. There had been no agreement 
among experts on how to define it. These authors considered it to be an aspect of both 
physical and mental health. The difficulty, they wrote, was in developing a measure of 
energy/fatigue that would be conceptually and empirically distinct from “similar concepts 
such as depression, positive affect, cognitive functioning, and sleep problems” (Stewart, 
Hays, & Ware, 1992, p. 147). In the final result, the “full of life” item was paired with the 
“a lot of energy” item to cover the energy side of the continuum. For our study with 
cancer patients, it was considered conceptually reasonable that responses to an item 
asking about feeling “full of life” would provide information about both depression and 
fatigue, so the item was allowed to cross-load in our model, thereby improving the fit. 
Like the inclusion of fatigue items as core symptoms in many depression scales, this “full 
of life” item from a fatigue scale cross-loading on depression is another example of the 
blurring of the conceptual distinction between depression and fatigue.  
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Yet when taken as a whole, results of the current study lend support to depression 
and fatigue existing as distinct entities. If the two were actually one, we would expect the 
CFA model with the two variables constrained to be equal to have the best empirical fit; 
yet that was not the case. Even more compelling, however, is the differential response to 
the intervention that specifically targeted depression and pain but not fatigue. For one 
thing, intervention arm membership had a significant effect on change in 3-month 
depression while it had no demonstrated effect on change in fatigue. Besides that, the 
stability path of the fatigue variable over the 3 months was of higher magnitude than that 
of depression; in other words, depression changed more than fatigue did. 
 In writing about fatigue in the context of MDD and medical disorders including 
but not exclusive to cancer, Arnold (2008) noted that fatigue is commonly a residual 
symptom in depressed patients who respond to antidepressants. She hypothesized that 
fatigue may involve neuronal circuits distinct from those that influence depressed mood. 
She encouraged studies of pharmacological treatments that specifically target fatigue 
within the context of MDD. The findings of the current study could be considered to be 
consistent with these ideas. 
As for the second question posed above about co-occurrence of CRF and 
depression, the current findings lend still further support to the well-established 
recognition of a strong association. The correlations in our relatively large sample of 
patients with various types of cancer were strong at baseline, and although the magnitude 
of the association between fatigue and depression declined over time as depression 
improved and fatigue did not, the correlation remained strong throughout.  
Regarding the third question about the existence of causal relationships, it has 
already been emphasized that our study found no support for a causal relationship 
between the two symptoms in either direction. That leaves us to ponder a scenario in 
which two distinct symptoms occur together frequently in the cancer context but may 
have no causal relationship. Without a causal connection, to what might we attribute the 
strong correlation of occurrence? 
As has been pointed out by previous researchers (Jacobsen et al., 2003), there may 
be a third factor that causes both fatigue and depression, or, more likely, multiple causes 
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that are common to both fatigue and depression in the cancer context. Numerous possible 
common causes have been advanced speculatively: for example, certain forms of cancer 
treatment such as biological response modifiers, increased levels of proinflammatory 
cytokines that occur as a result of cancer treatment, and certain types of cancer such as 
pancreatic (Fann et al., 2008; Jacobsen et al., 2003). A related but slightly different idea 
was formulated by Skapinakis and colleagues (2004) who speculated about possible 
explanations for the magnitude of longitudinal associations between depression and 
unexplained fatigue (not necessarily in cancer). These authors spoke of the possibility 
that fatigue and depression could be independent risk factors for each other in a manner 
resembling “an etiological vicious cycle.” A possible mechanism, they speculated, could 
be level of physical activity, which may decline in the context of either depression or 
fatigue. Physical activity is known to have a protective effect in depression, and 
deconditioning is believed to be important in the development of unexplained fatigue. 
These factors could interact in a complex way to exacerbate unexplained fatigue, or in the 
case of cancer, persistent cancer-related fatigue. Yet in such a scenario, one would expect 
the hypotheses of the current study to have been at least partially supported. 
The most plausible explanation for the findings of the current study may be the 
existence of a variable or, more likely, multiple variables that were not specified in the 
main model but that have a causal influence on levels of both fatigue and depression. It is 
quite likely that the cancer context comprises multiple factors that act as common causes 
to both depression and fatigue, which interact in complex ways to yield the strong 
associations such as those found in the INCPAD sample. 
 
 
 
Practice 
The current findings failed to support the perpetuating factors model presented in 
the background section that suggested that improvements in a cancer patient’s depression 
would lead to improvements in CRF. Rather, the practical implication of the current 
study is that treating depression may not be helpful in treating fatigue. This is consistent 
with NCCN treatment guidelines for CRF, which categorically state that antidepressants 
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are not recommended to lower fatigue (Berger et al., 2009). Two reviews of current 
treatments for CRF that endorsed antidepressants to treat fatigue were examined. One 
cited only “clinical observation” and no clinical trials to support the recommendation 
(Jacobsen et al., 2003); the other cited three placebo-controlled randomized trials of 
antidepressants that failed to improve CRF, but nevertheless recommended 
antidepressants as potentially helpful for fatigue if it is comorbid with depression 
(Escalante, 2010). The current study adds to an extant body of literature that suggests 
antidepressants are not helpful in treating fatigue, whether or not comorbid depression is 
present. No empirical studies were found that contradict this.  
Instead of supporting the approach of addressing CRF through depression 
treatments, the current findings suggest the importance of offering patients treatments 
that are specifically developed to target fatigue. This will require the focused attention of 
cancer care researchers as no gold standard of treatment has yet been established 
(Kangas, Bovbjerg, & Montgomery, 2008). Outside of the context of anemia, 
pharmacological treatments for CRF are in investigational stages. Psychostimulants (e.g., 
modafinil, which was developed for narcolepsy) may be promising and warrant more 
research (Berger et al., 2009); however, side effects such as restlessness, agitation, and 
insomnia may be especially problematic for CRF patients (Breitbart & Alici, 2008; 
Hanna et al., 2006). 
 NCCN guidelines position psychosocial and activity-based interventions as the 
first line of treatment for CRF (Berger et al., 2009). A systematic review of 119 studies 
combined with a meta-analysis of 57 RCTs concluded that both exercise and 
psychological interventions led to improvements in CRF. No significant differences were 
found between the two categories of interventions (Kangas et al., 2008). Jacobsen and 
colleagues (2007) conducted a systematic review and meta-analysis of 41 studies, 30 of 
which were RCTs, evaluating the efficacy of nonpharmacologic interventions for adult 
cancer patients in which fatigue was an outcome variable. The authors categorized 
treatments as either activity-based or psychological and rated quality indicators using 
criteria from the Cochrane Collaboration (Mulrow & Oxman, 1997). Activity-based 
treatments were exercise programs practiced either in a supervised setting or at home. 
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The 27 psychological interventions reviewed included group or individual cognitive-
behavioral therapy, educational programs, supportive-expressive therapy, and supportive 
therapy. Fifty percent of psychological trials and 44% of activity-based trials that were 
rated fair or better in quality resulted in significant findings favoring the intervention 
condition. The reviewers concluded their findings provided limited support for use of 
nonpharmacological interventions for CRF. 
Reviewers of the current evidence base for promising interventions have 
recommended further investigation of various categories of nonpharmacological 
treatment, grouped by NCCN guidelines into categories of cognitive-behavioral, 
behavioral , psycho-educational/educational, and supportive-expressive therapies. Both 
NCCN guidelines (Berger et al., 2009) and Mustian et al. (2007) support continuing 
investigation of nonpharmacologic behavioral interventions for CRF that include 
exercise, psychosocial support, stress management, energy conservation, nutritional 
therapy, sleep therapy, and restorative therapy. Kangas and colleagues (2008) 
recommended further trials of exercise and walking programs, restorative approaches, 
and cognitive-behavioral and supportive-expressive therapies.  
 
 
 
Limitations 
Although the current study contributes to understanding of the interrelationship of 
CRF with depression, several limitations must be taken into account. The use of a 
heterogeneous sample of cancer patients—individuals with a range of types of cancer and 
in various phases of treatment or survivorship—can be considered both a strength and a 
limitation. In its heterogeneity, the sample mimics the range of patients treated in 
oncology clinics, which enhances generalizability to a clinic setting. A particular strength 
of the INCPAD sample is that it included patients from both urban and rural centers. On 
the other hand, CRF may operate differently in specific types of cancer or phases of 
treatment, and its relationship to depression may differ accordingly. In the current study, 
mean scores for the vitality scale did not differ by type or phase of cancer, and neither 
type nor phase of cancer had a significant effect on change in fatigue or depression when 
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tested as potential control variables in the panel model. Sample size was insufficient, 
however, to afford confidence in these findings; therefore the conclusions may not apply 
to all types of cancer or phases of treatment. 
Another limitation may be the lack of multiple well-validated fatigue scales to 
support the latent variable fatigue in the current analysis. Having three such scales for 
depression was a strength. The lack of multiple full scales for fatigue was appropriately 
addressed by validating the vitality scale in a comparison with the Fatigue Symptom 
Inventory in a subsample. That plus the acceptable performance of the fatigue indicators 
in the CFA phase of the analysis suggests measurement was at least adequate in this 
analysis. 
It should also be acknowledged that it is possible that other types of treatment for 
depression (e.g., nonpharmacological) would have more of an effect on fatigue, both in 
the INCPAD study and in the other intervention trials that found no positive effects of 
antidepressant treatment on fatigue. The INCPAD study emphasized frequent monitoring 
of depression and pain, and for those who reported active symptoms, medications were 
recommended. Most of the treatment was pharmacological, which is similar to studies by 
others that have found that treating depression did not help with fatigue. Testing for 
effects on fatigue as a primary aim in trials of nonpharmacological treatments for 
depression would add to our understanding. It would be particularly interesting to see if 
depression treatments that tend to have broad effects on multiple symptoms such as 
anxiety and sleep disturbance would also help with fatigue (e.g., cognitive-behavioral 
therapy or acceptance- and mindfulness-based therapies). 
A final issue to take into account when considering these findings is the 
possibility of incorrect timing of the causal lag. Difficulties with specifying measurement 
occasions that match actual causal lags that are finite have been noted in the literature 
(Kline, 2005). Although three months may be a reasonable time in which to expect 
antidepressant treatment to improve depression, the current study does nothing to inform 
us as to whether the depression improvements might lead to changes in fatigue at time 
points beyond three months. 
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Future Directions 
A natural next step that would add confidence to the findings regarding causal 
effects is to extend the current analysis to a third wave of panel data. Three-wave and 
multiwave panels have been extolled as ideal for causal analysis and have been noted for 
potential to estimate reciprocal effects (Finkel, 1995). Sample size becomes even more of 
a consideration for 3-wave models, however, as there are additional parameters to be 
estimated and attrition typically tends to grow over more extended periods. 
Ideally, the current findings should be replicated in larger samples and with 
multiple validated scales for fatigue. A larger heterogeneous sample similar to that of the 
INCPAD study would allow the main analysis to be repeated with enough power to 
detect smaller effects, if they exist. More importantly, a much larger sample would allow 
the model to be tested by type and phase of cancer, which would lead to resolution of the 
unanswered question as to whether depression may have a causal influence on CRF in 
specific types or phases of cancer. A larger sample could also more readily be extended 
to multiple waves. It would also be informative to complete a similar study with a 
nonpharmacologic intervention for fatigue, and test for causal influences on depression.  
The current study underscores the need for future research attention to be focused 
on understanding CRF. Given how highly prevalent and disabling it is, surprisingly little 
is currently known about its etiology or how to help those who suffer from it. The current 
findings add new information to this under-studied but important issue. It is hoped that 
this work will be replicated and extended in ways that will inform the development of 
effective treatments. 
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Appendix A 
 
Reviews of Prevalence, Correlates, and Patterns of CRF 
 
 Demo-
graphic 
factors 
Cancer 
type or 
site 
Stage 
of 
cancer 
Type of 
treatment 
Bio 
markers 
Depression 
& anxiety 
Other 
Symptoms 
(e.g.sleep, 
pain, 
dyspnea)  
Other key findings 
 
Lawrence 
(2004) 
 
93 
studies 
Mixed Mixed Mixed Mixed - + + Occurrence rates ranged from 
4% to 91%. Cancer patients’ 
fatigue was higher than in 
comparison groups, both during 
and after treatment. CRF was  
also associated with 
psychosocial factors 
 
Prue 
(2006) 
 
44 
studies 
Mixed + - - + + + CRF persists following cancer 
treatment; survivor fatigue more 
severe than in comparison 
groups with no cancer history. 
Level of physical activity strongly 
negatively associated with CRF 
 
Servaes 
(2002)  
 
54 
studies 
- - - ?  + + Prevalence of CRF ranged from 
25% to 99%. In studies with 
comparison groups, fatigue in 
cancer patients was more 
frequent and severe than in 
groups with no cancer history 
 
+ = Found to be correlated;  - = Not correlated,  ? = Inconclusive 
 
Reprinted with permission from Psychosomatics, (Copyright 2009). American Psychiatric Publishing, Inc.
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Appendix B 
Summary of Studies Examining Relationship of Cancer-Related Fatigue With Depression and Anxiety 
Study Cancer Sample 
& Control 
group 
Treatment 
Status 
Fatigue 
Measure 
Depression 
Measure 
Anxiety 
Measure 
Fatigue-
Depression 
R or OR 
Fatigue-
Anxiety 
R or OR 
Key findings of study 
relevant to this review  
Andrykowski 
(1998) 
Longitudinal 
 
N = 88 
BC pts. Control 
= 88 age-
matched 
women without 
BC  
Post-treatment; 
mean is 28 
mos. 
Initial 
assessment & 
4-mo followup. 
Chalder 
Fatigue 
Scale; 
PFS 
CES-D  0.68 
p < 0.01 
 BC pts report more fatigue (but not 
depression) than controls. Fatigue may be 
chronic & unrelated to severity of 
treatment or time since completion. 
Blesch 
(1991) 
Cross-
sectional 
N = 77 
BC (44), or  
Lung cancer 
(33). 
Receiving 
chemotherapy 
or RT. 
VAS-
fatigue 
POMS-D POMS-
A 
0.46 
p = 0.0001 
 
0.40 
p = .0005 
 
Fatigue correlated with pain but not with 
psychological or biochemical variables. 
Depression and  anxiety correlated with 
one another.. 
Bower   
(2006) 
Longitudinal 
 
N = 763 
Long-term BC 
survivors 
 
Assessment at 
1-5,  and 5-10 
yrs after 
diagnosis 
SF-36 
vitality 
subscale 
CES-D  OR = 1.17 
P < 0.0001 
 Longitudinal predictors of fatigue 
included depression, cardiovascular 
problems, and  type of treatment. 34% 
reported significant fatigue 5-10 yrs after 
diagnosis; 21% at both assessment points, 
indicating persistence 
Bower 
(2000) 
Cross-
sectional 
N = 1,957 
Disease-free 
BC survivors 
1-to-5 yrs post-
treatment 
SF-36 
energy/fati
gue 
subscale 
CES-D  OR = 1.13 
p = .0001 
 The strongest predictor of fatigue was 
depression, followed by pain. Majority of 
participants did not experience more 
fatigue than general population, though a 
subgroup reported severe, persistent 
fatigue. 
Bruera 
(1989) 
Cross-
sectional 
N = 64 
Advanced BC 
Receiving 
chemotherapy 
or hormonal 
therapy 
Customize
d 4-test 
asthenia 
assessment 
SCL-90 
depression 
subscale 
SCL-90 
anxiety 
subscale 
0.62 
< 0.001 
0.42 
< 0.05 
Asthenia correlated with depression & 
psychological distress, but not with 
nutritional status, lean body mass, tumor 
mass, anemia, or type of treatment. 
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Study Cancer Sample 
& Control 
group 
Treatment 
Status 
Fatigue 
Measure 
Depression 
Measure 
Anxiety 
Measure 
Fatigue-
Depression 
R or OR 
Fatigue-
Anxiety 
R or OR 
Key findings of study 
relevant to this review  
Byar (2006) 
Longitudinal. 
 
N = 25  
Stage I or II 
BC  
Chemotherapy 
post-surgery. 
Assessed at 
base-line, 
treatment 4, & 
60-days and 1 
yr after 
treatment. 
PFS, 
Daily 
fatigue 
intensity 
item, 
SES 
fatigue 
items 
 
HADS-D HADS-
A 
NS-     T1 
0.618 -T2 
p = 0.002 
0.789 -T3 
p < 0.001 
0.510-T4 
p = 0.031 
NS-  T1 
NS- T2 
0.620-T3 
p = 0.004 
0.480- T4 
p = 0.044 
Fatigue levels were moderately intense 
during treatments & decreased over time. 
Anxiety was highest at baseline, & 
depression was highest during the 4th 
chemotherapy treatment. Higher fatigue 
compromises QoL. 
Chan (2005) 
Longitudinal 
 
N = 27 
Advanced lung  
cancer 
Receiving 
palliative RT. 
Assessed at 
baseline & 2 
times during 
RT. 
VAS  VAS  0.36-Base 
ns 
0.49 T2 
p < 0.05 
0.53 T3 
p < 0.01 
Prevalence of breathlessness, fatigue, & 
anxiety ranged from 59% to 96%, with 
intensity becoming worse at Time 2 and 
3. This symptom cluster had high internal 
consistency across 3 time points. 
 Dimeo   
(2004) 
Cross-
sectional 
N = 71 
Hematological 
malignancies 
without  
relapse 
At least 3 mo 
after treatment  
FACT-F CES-D  0.84 
p < 0.0001 
 Fatigue was related to depression & 
reduced performance status. No 
correlation between fatigue & impairment 
of thyroid function, anemia, or persistent 
activation of immune system. 
Dimeo 
(1997) 
Cross-
sectional 
N = 78 
Solid tumors or 
hematological 
malignancies 
 
 POMS-F POMS-D 
SCL-90 
Depressio
n 
SCL-90 
Anxiety 
0.61 POMS-
D 
0.68 SCL-90 
p < 0.001 
0.63 
p < 0.001 
Fatigue weakly associated with physical 
performance but strongly correlated with 
depression, somatization, & anxiety. 
Lower physical performance was 
associated with higher scores in 
psychological variables. 
Fernandes   
(2006) 
Cross-
sectional 
 
N = 25 
Female 
inpatients. 
Control N = 25 
Healthy 
volunteers 
Varied EORTC 
QLQ-C30 
fatigue 
subscale, 
BFS 
HADS-D HADS-
A 
0.63 
p = 0.002 
0.37 
ns 
Fatigue severity was correlated with low 
QoL, depression, constipation, & 
decreased physical function. Fatigue 
severity was not related to impairment in 
sleep & circadian rhythm. 
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Study Cancer Sample 
& Control 
group 
Treatment 
Status 
Fatigue 
Measure 
Depression 
Measure 
Anxiety 
Measure 
Fatigue-
Depression 
R or OR 
Fatigue-
Anxiety 
R or OR 
Key findings of study 
relevant to this review  
Fillion   
(2003) 
Cross-
sectional. 
 
N = 604 
BC  
Prostate cancer  
RT or other 
therapy 
underway or 
recently 
completed 
MFI-15 HADS-D HADS-
A 
0.58 
significant 
but no p-
value  
0.37 
significant 
no p-value 
This was validation study: the MFI-5 
showed good psychometric qualities for 
assessment of CRF 
Fleer (2005) 
Longitudinal 
 
N = 52 
Stage 1 or 
disseminated 
non-
seminomatous 
testicular tumor  
Within 1 mo.  
orchidectormy 
& 3 & 12 mo 
later 
MFI-20  STAI  0.51 
p < 0.001 
 
 
Older age, trait anxiety &  early fatigue 
predicts fatigue. 1 yr after orchidectomy. 
Trait anxiety had causal effect on all 
fatigue subscales. Fatigue is not enduring 
problem in testicular cancer, with 
treatment only having an impact on 
fatigue levels shortly after treatment. 
Fossa  (2003) 
Cross-
sectional. 
Mail survey 
comparing 3 
groups 
N = 1038 
survivors 
791 testicular 
cancer &247 
Hodgkin’s 
disease Control 
N = 1112 
general 
population 
Testicular 
cancer 
survivors 
(TCS) treated 
at least 4 yrs 
earlier.  
FQ HADS-D HADS-
A 
OR = 1.1.83 
P < 0.001 
OR = 
1.190 
P < 0.001 
16% of long-term survivors of testicular 
cancer had chronic fatigue, with age, 
anxiety, depression, & comorbidity as 
predictors. The highest & lowest mean 
scores of anxiety & depression were in 
the youngest TCS.  Anxiety is a larger 
problem among TCS than depression, 
especially among the youngest. 
Fox (2006) 
Cross-
sectional 
N = 51 
Lung cancer 
recruited via 
web 
Varied; 94% 
had undergone 
some treatment 
pre-study 
SF-36 SF-36  0.44 
p = 0.01 
 Depression, fatigue, & pain found in 
majority of survivors, with pain being the 
least common. Fatigue was the most 
intense & correlated with depression.  
Gaston-
Johansson 
(2000) 
Cross-
sectional 
analysis of 
RCT  
N = 110 
Stage II, III or 
IV BC 
 
Scheduled for 
autologous 
bone marrow 
transplantation 
VAS BDI STAI 0.32 
p < 0.01 
0.43 
p < 0.001 
Bundled intervention (education, 
cognitive restructuring, & relaxation with 
imagery) reduced fatigue & nausea. Both 
groups had mild depression after 
treatment. The treatment group 
experienced mild anxiety compared to 
moderate anxiety in controls.  
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Study Cancer Sample 
& Control 
group 
Treatment 
Status 
Fatigue 
Measure 
Depression 
Measure 
Anxiety 
Measure 
Fatigue-
Depression 
R or OR 
Fatigue-
Anxiety 
R or OR 
Key findings of study 
relevant to this review  
Geinitz 
(2004) 
Longitudinal 
N = 38 
Localized BC  
after 
radiotherapy 
Assessment at 
8 days before 
RT &  
2 mo and 2.5 
yrs post-
treatment 
FAQ 
VAS for 
fatigue 
HADS-D HADS-
A 
0.56 & 0.62 
p < 0.001 
0.62 &  
0.47 
p < 0.001 
& 
p = 0.003 
Chronic fatigue correlated closely with 
psychological distress. Pretreatment 
fatigue, anxiety and depression were risks 
for chronic fatigue. Fatigue 2.5 yrs after 
RT did not increase above baseline levels 
Geinitz 
(2001) 
Longitudinal 
N = 41 
BC 
Post-operative 
RT after 
surgery. 
Assessed 
before, weekly 
during, & 2 
mo. after end 
of RT 
FAQ 
VAS, 
intensity 
HADS-D HADS-
A 
0.56 
p < 0.001 
 
 
0.67 
p < 0.001 
 
 
Fatigue increased during RT. Neither 
anxiety nor depression increased during 
RT. VAS correlated with HADS-D only 
for wks 2 & 5 (0.48 & 0.44) & .with 
HADS-A only for wks 2 & 5 (0.43 & 
0.41) 
Geiser (2007) 
Longitudinal 
N = 54 
Cancer pts with 
anemia 
Control N = 25 
Non-anemic pts 
Treatment 
group assessed 
before start of 
epoetin alfa 
treatment & at 
4, 8, 12, & 26 
wks 
FACT-F HADS-D HADS-
A 
0.67 - 0.73 
mean = 0.70 
p not 
reported 
Not 
reported 
Depression & QoL before treatment 
correlated with reduction of fatigue 
during treatment. Anxiety did not 
correlate.  
Glaus (1998) 
Cross-
sectional 
 
N = 77 
Cancer pts. 
Controls 77 
healthy hospital 
workers 
Currently 
receiving 
treatment 
FAQ HADS-D HADS-
A 
0.54 
no p-value  
0.48 
no p-value  
This is a scale development study. FAQ 
was found to be reliable & valid. 
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Study Cancer Sample 
& Control 
group 
Treatment 
Status 
Fatigue 
Measure 
Depression 
Measure 
Anxiety 
Measure 
Fatigue-
Depression 
R or OR 
Fatigue-
Anxiety 
R or OR 
Key findings of study 
relevant to this review  
Haghighat  
(2003) 
Cross-
sectional 
N = 112 
BC 
During 
treatment or at 
follow-up exam 
CFS HADS-D HADS-
A 
OR = 1.3 
P = 0.003 
OR = 1.2 
P = 0.04 
Prevalence of fatigue, anxiety, & 
depression was 49%, 16% & 32% 
respectively. Fatigue predicted by anxiety 
depression, pain, tamoxifen use, having 
mastectomy. 
 
 
Hann (2000) 
Cross-
sectional  
N = 342 
Cancer pts 
Varied. FSI CES-D  0.55 
p < 0.01 
 FSI was found to be a reliable &  valid 
measure of fatigue in a heterogenous 
sample of cancer pts. 
Hann (1999) 
Longitudinal 
N = 31 
BC 
Control N = 49 
women with no 
cancer history 
Undergoing 
Autologous 
Stem Cell 
Transplantation 
(ASCR). 
POMS-F 
FSI 
CES-D STAI 0.77 
p < 0.001 
0.52 
p < 0.01 
 
BC pts reported worse depression than 
controls & pts’ depression worsened over 
course of treatment. Pts’ anxiety was not 
significantly higher than controls & did 
not change during ASCR. Worse fatigue 
during ASCR was associated with worse 
depression & anxiety. 
Hann (1998) 
Longitudinal 
N = 220 
Disease-free 
BC pts 
 
Varied  FSI CES-D STAI 0.46 
p < 0.001 
  
0.48 
p < 0.001 
 
FSI  found to be a reliable &  valid 
measure of fatigue. Women with BC had 
more fatigue during &  after treatment 
than other women of similar age. 
Hann (1997) 
Cross-
sectional 
N = 43 
BC 
Control N = 43 
women with no 
cancer history 
Disease free,  3 
mo. after bone 
marrow 
transplant 
(BMT).  
POMS-F 
FSI 
CES-D STAI 0.80 
p < 0.001 
0.65 
p < 0.001 
Fatigue was more frequent & severe for 
BMT recipients & had greater impact on 
functioning & QoL. Fatigue was more 
severe for those in whom more time had 
passed since BMT.  
Hwang   
(2003) 
Cross-
sectional 
N = 180 
Male cancer pts 
Varied BFI 
FACT-F 
MSAS-SF 
lack-of-
energy 
item 
Zung SDS 
(dropped 
3 somatic 
items) 
 -0.70  
(BFI global) 
P < 0.0001 
-0.68 FACT-
F 
0.61 MSAS 
 All three fatigue measures showed strong 
correlation with depression. The lack-of-
energy single item yielded similar 
information as multi-item scales & may 
provide a simple way to assess fatigue. 
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Study Cancer Sample 
& Control 
group 
Treatment 
Status 
Fatigue 
Measure 
Depression 
Measure 
Anxiety 
Measure 
Fatigue-
Depression 
R or OR 
Fatigue-
Anxiety 
R or OR 
Key findings of study 
relevant to this review  
Kim (2006) 
Longitudinal. 
Secondary 
analysis of 
trial 
N = 525 
Cancer patients 
 
Chemotherapy 
underway 
FSCL CES-D POMS-
SF 
Anxiety 
Scale 
0.67 T1 
0.72 T2 
0.73 T3 
0.71 T4  
p not 
reported 
 2 dimensions of psychological factors—
arousal & valence—predicted changes in 
fatigue & depression. Fatigue changes 
depended more on valence; depression 
changes on both valence & arousal. 
Kirsh (2001) 
Cross-
sectional.  
N = 52 
Cancer pts in 
urban & rural 
centers 
Varied. Zung  item, 
“I get tired 
for no 
reason.” 
Also, 
FACT-An 
Zung SDS  0.63 
p < 0.0001 
(Zung item) 
 The single fatigue item from the Zung 
SDS was highly correlated with the Zung 
SDS and the FACT-An. Use of the single 
Zung fatigue item as a brief measure for 
fatigue was supported. 
Loge (2000) 
Cross-
sectional 
N = 421 
Hodgkin’s 
disease 
survivors 
Varied. FQ HADS-D HADS-
A 
0.49 
p < 0.001 
0.44 
p < 0.001 
26% of Hodgkin’s disease survivors had 
substantial fatigue for ≥ 6 mo. These pts 
had higher anxiety & depression, but not 
more past psychiatric problems. 
Meek (20000 
Longitudinal 
N = 212 
Cancer patients 
Pts receiving 
treatment for 
cure or local 
control. 
treatment 
POMS-F 
MAF 
LFS 
MFI 
POMS-D POMS-
T 
0.53 POMS-
F 
0.53 MAF 
0.41 LFS-F 
- 0.37 MFI 
p < 0.05 
0.57 
POMSF 
0.52 MAF 
0.47 LFS-
F 
- 0.40 
MFI 
p < 0.05 
 
Results supported validity of three of four 
fatigue scales tested; MFI required further 
testing. 
Mock (1997) 
Longitudinal 
N = 46 
Breast cancer 
pts 
Post surgery &  
at start, 
midpoint and 
end of 6-wk RT  
PFS VAS VAS 0.61 
p < 0.001 
0.60 
p < 0.001 
Exercise group had significant 
improvements in physical functioning & 
symptom intensity, particularly fatigue, 
anxiety, & sleep problems. 
Morant 
(1996) 
Cross-sect. 
N = 225 
Cancer pts 
Varied. LASA LASA  0.48 
p < 0.0001 
 Fatigue correlated with mood, weakness, 
lack of concentration, lack of appetite, 
insomnia, & pain. 
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group 
Treatment 
Status 
Fatigue 
Measure 
Depression 
Measure 
Anxiety 
Measure 
Fatigue-
Depression 
R or OR 
Fatigue-
Anxiety 
R or OR 
Key findings of study 
relevant to this review  
Morrow 
(2003) 
Longitudinal 
N = 549 
235 
randomized to 
placebo 
condition 
Receiving 
chemotherapy. 
Assessment at 
cycles 2, 3, &  
4 
FSCL 
MAF 
POMS-F 
CES-D 
POMS-D 
 0.61 
P < 0.01 
 Difference found between treatment and 
control groups in depression, but no 
difference was detected in fatigue. 
Munch  
(2006) 
Cross-
sectional 
 
N = 130 
Advanced 
cancer pts 
Palliative care MFI-20 
Subscales 
Physical 
HADS-D HADS-
A 
0.52 
p < 0.0001 
0.23 
p = 0.011 
Fatigue levels were high. Depressed pts 
had higher levels on 4 fatigue subscales 
(general, mental, reduced activity, 
reduced motivation) but not on physical 
fatigue 
Okuyama 
(2001) 
Cross-
sectional 
N = 157 
Advanced lung 
cancer pts 
No active 
cancer in 
preceding 4 
wks 
CFS 
FNS 
HADS-D HADS-
A 
OR = 1.24 
p = 0.001 
 Half the sample had clinical fatigue. 
Dyspnea on walking, appetite loss, & 
depression were correlated. 
Okuyama 
((2000) 
Cross-
sectional 
N = 307 
Cancer pts 
Varied CFS HADS-D HADS-
A 
0.69 
p < 0.001 
0.69 
p < 0.001 
Results suggest the CFS is a brief, valid, 
and feasible measure of CRF. 
Okuyama 
(2000) 
Cross-
sectional 
N = 134 
Disease-free 
BC  
Post-surgery &  
not in active 
treatment  
CFS HADS-D  0.63 
p < 0.001 
0.52 
p < 0.001 
Depression, dyspnea, & insufficient sleep 
accounted for 46% of fatigue variance. 
Disease &  treatment variables (e.g., 
disease stage, time since surgery) were 
not correlated with fatigue. 
Passik   
(2002) 
Cross-
sectional 
 
N = 200 
100 pts from 
urban, 100 
from  rural sites 
Receiving 
chemotherapy 
FACT-F Zung-SDS 
(dropped 
9 somatic 
items) 
 -0.66 
p < 0.001 
 
 Depressed pts more likely to have heard 
about fatigue interventions, and wanted 
medications for fatigue  
Few urban-rural differences were noted. 
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Measure 
Depression 
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Anxiety 
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Fatigue-
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R or OR 
Fatigue-
Anxiety 
R or OR 
Key findings of study 
relevant to this review  
Pirl (2008) 
Longitudinal 
N = 52 
Men with 
advanced or 
recurrent 
prostate cancer 
Receiving 
hormone 
therapy. 
Assessed 
pretreatment, 6 
mo & 12 mo 
FSS BDI  0.34 *T1 
0.69** T2 
0.58** T3 
*p = 0.02 
**p = 0.001 
 Fatigue increased significantly over the 
study period but depression do not 
change. 
Prieto   
(2006) 
Longitudinal 
N = 220 
Hematologic 
cancer  
Hospitalized 
for  stem cell 
transplant. 
Assessment at 
admission, day 
of transplant, & 
7- & 14-day 
post-surgery 
Validated 
1-item 
energy 
scale 
HADS-D HADS-
A 
-0.45**  T1 
-0.25**  T2 
-0.27**  T3 
-0.22*    T4 
*   p < 0.01 
**  p < 0.001 
-0.26** T1 
-0.20*   T2 
-0.21*   T3 
-0.16     T4 
*   p < 0.01 
**  p< .001 
Depression was variable most 
consistently & strongly associated with 
fatigue, measured using an energy level 
scale validated to capture the most 
physical dimension of fatigue. Baseline 
depression showed significance or a trend 
toward significance in predicting 
subsequent fatigue scores during 
hospitalization. 
 Redeker 
(2000) 
Cross-
sectional 
N = 263 
Cancer pts  
 
Undergoing 
chemotherapy 
SDS POMS-D POMS-
T 
0.43 
p < 0.001 
0.44 
p < 0.001 
Symptoms & psychological variables 
explained 47% of variance in QoL, with 
the largest proportion explained by 
depression. Fatigue & insomnia explained 
only 4% 
Respini   
(2003) 
Cross-
sectional 
 
N = 77 
Cancer 
outpatients age 
60 and older 
During 
treatment with 
chemotherapy 
or pamidronate 
FSI GDS  0.29 
p < 0.01 
 
 Fatigue was almost universal. Fatigue 
disruptiveness higher for women (p < 
0.007). Depression was signify-cantly 
related to fatigue severity & 
disruptiveness. 
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& Control 
group 
Treatment 
Status 
Fatigue 
Measure 
Depression 
Measure 
Anxiety 
Measure 
Fatigue-
Depression 
R or OR 
Fatigue-
Anxiety 
R or OR 
Key findings of study 
relevant to this review  
Reuter 
(2006) 
Cross-
sectional 
N = 353 
BC recently 
diagnosed 
Post-surgery  & 
within 12-mo. 
of diagnosis 
POMS-F HADS-D  0.59 
P < 0.001 
 Fatigue was positively associated with 
depression & pain but inversely related to 
age. The association between coping & 
fatigue was weak. 
Roscoe   
(2002) 
Longitudinal. 
 
N = 78 
BC pts 
At 2nd & 4th on-
study 
chemotherapy 
cycles. 
Assessment 7 
days after each 
treatment. 
Circadian 
rhythm 
monitored over 
72-h period. 
MAF 
FSCL 
CES-D 
HDI 
 FSCL, CES-D 
0.63 
FSCL&HDI 
0.66 
MAF,CES-D 
0.66 
MAF&HDI 
0.68 
(All  p < 0.01) 
 Changes in the fatigue and depression 
measures from the 2nd treatment to the 4th 
correlated with changes in circadian 
rhythm. Suggests circadian rhythm 
disruption may contribute to fatigue & 
depression in cancer 
Schneider 
(1998) 
Cross-
sectional 
N = 54 
Cancer pts 
Receiving RT 
or 
chemotherapy 
MFI-20 BDI  0.56 
p < 0.001 
 In this construct validation study, MFI-20 
was found to be a potentially useful 
measure of  fatigue. 
 
Schumacher 
(2002) 
Longitudinal 
N = 101 
Pts newly 
diagnosed with 
acute myeloid 
leukemia 
Undergoing 
treatment. 
Assessment at 
12 sequential 
time points 
over 3 years. 
EORTC 
QLQ-C30 
fatigue 
subscale, 
 
POMS-D  0.38** T2 
0.38** T3 
0.37*   T4 
0.34*   T5 
0.52**  T7 
0.47**  T8 
0.39*    T9 
n.s. T1,T6, 
T10,T11,T12       
*p < 0.05 
**p < 0.01 
 Depression was significantly inversely 
correlated with emotional functioning 
subscale of the QLQ-C30 throughout the 
study but its correlation with the fatigue 
subscale was nonsignificant at 5 of 12 
time points.  
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& Control 
group 
Treatment 
Status 
Fatigue 
Measure 
Depression 
Measure 
Anxiety 
Measure 
Fatigue-
Depression 
R or OR 
Fatigue-
Anxiety 
R or OR 
Key findings of study 
relevant to this review  
Servaes   
(2007) 
Longitudinal. 
N = 150 
Disease-free 
BC survivors 
diagnosed 
before age 50. 
≥ 6-mo post-
treatment. and 
then monthly 
for 2 yrs 
POMS-F BDI-
primary 
care 
STAI N/A 0.612 
P < 0.001 
Fatigue persisted in a quarter of disease-
free cancer pts during 2-yr follow-up. 
High anxiety, impairment in role 
functioning, & low sense of control over 
fatigue at baseline predicted persistent 
fatigue. 
 
Servaes 
(2000) 
Cross-
sectional. 
N = 85 
Disease-free 
cancer pts 
Comparison N 
= 16 CFS pts 
≥ 6-mo post-
treatment 
CIS BDI STAI 0.73 
p not 
reported 
0.60 
p not 
reported 
Severity of fatigue in cancer pts was 
comparable to that of pts with CFS. 
Severe fatigue is associated with 
problems of concentration and 
motivation, reduced physical activity, 
emotional health, and pain. Highest 
frequence of severe fatigue was in pts 
treated with RT. 
 
Smets 
(1998A) 
Longitudinal. 
Same sample  
as Visser 
1998 
N = 250 
Cancer pts 
receiving RT. 
Assessment 
before RT, 
every 2 wks 
during 
treatment, &  2 
wks post-RT..  
MFI-20 CES-D  0.43 
p < 0.001 
 Fatigue  increased over the course of RT, 
followed by a decrease after RT ended, 
suggesting an acute radiation effect . Pre-
treatment fatigue was greatest predictor of 
post-treatment fatigue; fatigue after RT 
only slightly but significantly higher than 
before RT 
Smets 
(1998B) 
Cross-
sectional 
N = 154 
Disease-free 
cancer patients 
after RT. 
Control N = 
139 
General 
population 
9 mo after RT. MFI-20 CES-D  0.49 
p < 0.001 
 Fatigue in disease-free cancer pts did not 
differ from general population, although 
39% listed fatigue as one of their 3 most 
distressing symptoms, & 34% reported 
fatigue following treatment was worse 
than expected. Overall QoL negatively 
related to fatigue (r = -0.46). 
Smets (1996) 
Cross-
sectional 
N = 116 
Cancer pts 
During RT MFI-20 HADS-D 
w/o item 8 
HADS-
A 
0.77 
p < 0.001 
0.51 
p < 0.001 
Results support the validity of the MFI-
20. 
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group 
Treatment 
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R or OR 
Fatigue-
Anxiety 
R or OR 
Key findings of study 
relevant to this review  
Stein (1998) 
Longitudinal.  
 
N = 275 
BC pts 
Control N = 70 
Women with 
no cancer 
history 
Received or 
under-going 
RT,  BMT, or 
chemotherapy 
MFSI CES-D STAI 0.68 
p < 0.05 
0.58 
p < 0.05 
The MFSI may be useful in identifying 
patterns of fatigue within individuals & 
across treatment modalities. 
Stone (2001) 
Longitudinal. 
N = 69 
Pts with breast 
or prostate 
cancer 
Assessment 
prior to starting 
RT &  within 1 
wk of 
completion 
FSS 
BFS 
EORTC  
QLQ-C30 
HADS-D 
w/o item 8 
HADS-
A 
0.75 
p <0.001 
(at baseline) 
0.50 
p < 0.001 
(at 
baseline) 
 
No increase in FSS scores, but modest 
significant increase in 3 other measures of 
fatigue. Combination of fatigue & anxiety 
at baseline predicted 54% of variation in 
fatigue at completion of RT. Depression 
had strongest association with fatigue 
severity. 
Stone (2000) 
Cross-
sectional. 
N = 227 
Prostate cancer, 
BC, non-small-
cell lung 
cancer, or 
advanced 
cancer 
Control N = 98 
Pts about to 
begin receiving 
treatment 
except for 
group with 
advanced 
cancer, who 
were 4 wks 
post-treatment 
FSS 
EORTC  
QLQ-C30 
HADS-D 
w/o item 8 
HADS-
A 
0.67 
p < 0.001 
0.41 
p < 0.001 
Severe fatigue was present in 15%, 16%, 
50%, & 78%, respectively, of pts recently 
diagnosed with BC, recently diagnosed 
with prostate cancer, inoperable non-
small cell lung cancer, & palliative care 
inpatients. Psychological distress, 
dyspnea, pain & overall disease burden 
accounted for 56% of fatigue. 
Stone (2000) 
Longitudinal 
N = 62 
Prostate cancer 
patients 
Pts starting 
first-line 
hormone 
therapy. 
Assessment at 
start of 
hormone 
therapy and 3 
mo later. 
FSS 
EORTC-
QLQ C30 
BFS 
VAS 
HADS-D 
w/o item 8 
HADS-
A 
0.46  
P < 0.001 
FSS 
0.52 
P < 0.001 
Mean FSS scores increased after 3 mo 
treatment. Anxiety/depression symptoms 
accounted for 28% of variance in fatigue 
at baseline. Increases in fatigue did not 
appear to be related to increases in 
psychological complaints. 
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Fatigue-
Anxiety 
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Key findings of study 
relevant to this review  
Stone (1999) 
Cross-
sectional 
N = 95 
Inpatients with 
advanced 
cancer 
Control N = 98 
without cancer 
No RT or 
chemotherapy 
in previous 4 
wks. 
FSS HADS-D 
w/o item 8 
HADS-
A 
0.16 
ns 
0.16 
ns 
75% of advanced cancer pts had severe 
subjective fatigue (fatigue greater than 
that of 95% of the control group). Fatigue 
severity associated with pain & dypsnoea; 
anxiety & depression were significant 
correlates only in controls. 
Sugawara   
(2005) 
Cross-
sectional 
 
N = 79 
BC pts w/o 
major 
depression & 
disease free 3 
yrs post 
surgery 
Disease-free 
status & 
receiving no 
therapy other 
than tamoxifen 
CFS POMS-D STAI 0.36 
p < 0.01 
0.36 
p < 0.01 
36.7% of disease-free BC pts without 
major depression exhibited fatigue, which 
was strongly associated with neuroticism. 
Depressive symptoms & anxiety were 
also significantly associated. 
Tchekmedyia
n (2003) 
Longitudinal  
N = 250 
Lung cancer 
pts with 
anemiar 
On 
chemotherapy. 
Assessment at 
baseline & 
after 4 wk of 
treatment. 
FACT-F BSI-
Depressio
n 
BSI-
Anxiety 
-0.44 
p < 0.001 
-0.45 
p < 0.001  
Improvements in fatigue were associated 
with reductions in anxiety & depression. 
In a multiple regression model of change 
in anxiety & depression, change in fatigue 
was the only significant variable 
Tsai   (2007) 
Cross-
sectional. 
 
N = 77 
Terminally ill 
cancer 
Institutional 
hospice 
POMS-F HADS-D HADS-
A 
0.73 
p < 0.0001 
0.54 
p < 
0.0001 
Terminally ill pts had moderate to severe 
levels of fatigue. Fatigue was associated 
with overall symptom distress, 
depression, anxiety, & performance 
status. 
Visser (1998) 
Longitudinal 
N = 250 
Cancer pts 
scheduled for 
RT 
In RT.  
Assessment 2 
wks pre- 
treatment, 2 
wks post 
treatment, 9 mo 
later. 
MFI-20 CES-D 
(mood 
only) 
 0.35 T1 
0.43 T2 
0.48 T3 
p < 0.001 
 
 Just after RT, fatigue increased or 
remained stable, while depression 
decreased. 9 mo later, fatigue had 
decreased while depression was stable. 
No strong causal relationship was found 
between depression & fatigue. 
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Fatigue-
Anxiety 
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Key findings of study 
relevant to this review  
Wu (2006) 
Cross-
sectional 
N = 172 
BC pts 
Undergoing 
chemotherapy 
WCFS GDS  0.60 
p not 
reported 
 In this scale development study, the 
revised WCFS was found to be reliable & 
valid. 
Young 
(2006) 
Cross-
sectional. 
N = 69 
Disease-free 
BC pts 
At least 6 mo 
post-treatment 
MFSI 
FSI  
Structured 
interview 
HADS-D HADS-
A 
0.78, 0.79 
p < 0.01 
 
0.70, 0.75 
p < 0.01  
19% met draft ICD-10 criteria for cancer-
related fatigue. Psychological distress & 
beliefs about activity predicted fatigue 
directly. 
    
 
BDI  Beck Depression Scale 
BFI  Brief Fatigue Inventory 
BFS  Bi-dimensional Fatigue Scale 
BSI  Brief Symptom Inventory 
CFS  Cancer Fatigue Scale 
CES-D  Center for Epidemiological Studies Depression Scale 
CIS  Checklist Individual Strength 
EORTC  European Organization for Research & Treatment of Cancer 
30-Item  
FACT-F Functional Assessment of Cancer Therapy- Fatigue Subscale 
FAQ  Fatigue Assessment Questionnaire 
FNS  Fatigue Numerical Scale 
FQ  Fatigue Questionnaire 
FSCL  Fatigue Symptom Checklist, 30-item 
FSI  Fatigue Symptom Inventory 
FSS  Fatigue Symptom Severity 
GDS  Geriatric Depression Scale 
HADS-A Hospital Anxiety & Depression Scale – Anxiety 
HADS-D Hospital Anxiety & Depression Scale – Depression 
HDI  Hamilton Depression Inventory 
LASA  Linear Analogue Self-Assessment 
LFS-F  Lee Fatigue Scale-Fatigue subscale 
MAF  Multidimensional Assessment of Fatigue 
MSAS-SF Memorial Symptom Assessment Scale Short Form 
MFI-20  Multidimensional Fatigue Inventory 
MFI-15  Mulitdimensional Fatigue Inventory – Short form 
MFSI Multidimensional Fatigue Symptom Inventory 
PFS  Piper Fatigue Scale 
POMS-D Profile of Mood States depression-dejection subscale 
POMS-F  Profile of Mood States fatigue-inertia scale 
POMS-T Profile of Mood States-tension/anxiety scale 
SCL-90   Symptoms Checklist – 90 
SDS  Symptom Distress Scale 
SF-36  Short-Form 36 Health Status Survey 
SES  Symptom Experience Scale 
STAI  Spielberger Trait Anxiety Inventory 
VAS  Visual Analog Scale, 100-meter 
WCFS  Wu Cancer Fatigue Scale 
Zung SDS Zung Self-Rating Depression Scale 
General fatigue scores are used for correlations when multiple fatigue types are reported 
 
BC =   BC 
CFS =  Chronic Fatigue Syndrome 
N/A =     Not Available 
RCT =   Randomized controlled trial 
RT=  Radiotherapy 
QoL=  Quality of life 
BMT =   Bone marrow transplantation 
Pt(s) =   Pt(s) 
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(Andrykowski, Curren, & Lightner, 1998; Blesch et al., 1991; Bower et al., 2006; Bower et al., 2000; Bruera et al., 1989; Byar, Berger, 
Bakken, & Cetak, 2006; Chan et al., 2005; Dimeo et al., 2004; Dimeo et al., 1997; Fernandes, Stone, Andrews, Morgan, & Sharma, 2006; 
Fillion, Gelinas, Simard, Savard, & Gagnon, 2003; Fleer, Sleijfer, Hoekstra, Tuinman, & Hoekstra-Weebers, 2005; Fossa, Dahl, & Loge, 
2003; Fox & Lyon, 2006; Gaston-Johansson et al., 2000; Geinitz et al., 2001; Geinitz et al., 2004; Geiser et al., 2007; Glaus, 1998; 
Haghighat, Akbari, Holakouei, Rahimi, & Montazeri, 2003; Hann et al., 2000; Hann et al., 1999; Hann et al., 1998; Hann et al., 1997; 
Hwang, Chang, Rue, & Kasimis, 2003; Kim, Hickok, & Morrow, 2006; Kirsh, Passik, Holtsclaw, Donaghy, & Theobald, 2001; Loge, 
Abrahamsen, Ekeberg, & Kaasa, 2000; Meek et al., 2000; Mock et al., 1997; Morant, 1996; Morrow et al., 2003; Munch et al., 2006; 
Okuyama, Akechi, Kugaya, Hitoshi et al., 2000; Okuyama, Akechi, Kugaya, Okamura et al., 2000; Okuyama et al., 2001; Passik et al., 
2002; Pirl, 2008; Prieto et al., 2006; Redeker, Lev, & Ruggiero, 2000; Respini et al., 2003; Reuter et al., 2006; Roscoe et al., 2002; 
Schneider, 1998; Schumacher et al., 2002; Servaes, Gielisson, Verhagen, & Bleijenberg, 2007; Servaes et al., 2000; Smets et al., 1996; 
Smets, Visser, Willems-Groot, Garssen, Oldenburger et al., 1998; Smets, Visser, Willems-Groot, Garssen, Schuster-Uitterhoeve et al., 
1998; Stein, Martin, Hann, & Jacobsen, 1998; Stone et al., 1999; Stone, Hardy et al., 2000; Stone, Richards, A'Hern, & Hardy, 2000; Stone 
et al., 2001; Sugawara et al., 2005; Tchekmedyian et al., 2003; Tsai et al., 2007; Visser & Smets, 1998; Wu, Wurwich, & McSweeney, 
2006; Young & White, 2006) 
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Appendix C 
 
Bivariate Correlations of Latent Variable Indicators Across Both Time-Points 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
1.  sfenerT1 ♦ .41   .48    .49   -.36    -.47    -.37    .41    .39    .33    .32    -.31    -.32    -.33    
2.  sflifeT1  ♦ .29    .35    -.39    -.46    -.53    .29    .41    .30    .25    -.25    -.26    -.30    
3.  sfwornT1   ♦ .74    -.34    -.46    -.33    .39    .26    .44    .38    -.31    -.30    -.27 
4.  sftireT1    ♦ -.40 -.51 -.40    .36  .30 .43 .43 -.34 -.28 -.30 
5.  PHQ9T1     ♦ .74 .65 -.27 -.34 -.36 -.24 .44 .43 .44 
6.  SCL20T1      ♦ .74 -.35 -.42 -.41 -.31 .53 .58 .53 
7.  MHI3T1       ♦ -.27 -.43 -.33 -.25 .46 .43 .56 
8.  sfenerT2        ♦ .53 .53 .56 -.48 -.51 -.44 
9.  sflifteT2         ♦ .49 .45 -.54 -.59 -.63 
10.sfwornT2          ♦ .78 -.60 -.58 -.51 
11. sftireT2           ♦ -.54 -.50 -.46 
12. PHQ9T2            ♦ .85 .73 
13. SCL20T2             ♦ .76 
14. MHI3T2              ♦ 
 
Note. Fatigue indicators are sfener, sflife, sfworn, sftire. Depression indicators are PHQ9, SCL20, MHI3. T1 = baseline; T2 = 3 months. Negative 
correlations suggest a positive association between fatigue and depression because higher vitality scores suggest less fatigue whereas higher 
depression scores suggest worse symptoms. All correlations are significant at the 0.01 level (2-tailed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VITA 
 100 
 
 
 
 
 
VITA 
 
Linda F. Brown 
 
 
 
EDUCATION 
 
August 2011   PhD, Clinical Psychology (APA Accredited) 
 Indiana University-Purdue University Indianapolis (IUPUI) 
    
Dissertation Title: Depression and Cancer-Related Fatigue: A 
Cross-Lagged Panel Analysis of Causal Effects. Defended May 
2010 
 
2010 - 2011  Predoctoral Internship (APA Accredited) 
  Geisinger Medical Center, Danville, PA  
 
2007   MS, Clinical Rehabilitation Psychology 
Indiana University-Purdue University Indianapolis 
    
2005 MA, Liberal Studies 
 University of Southern Indiana, Evansville, IN 
 
2000   BA, Psychology  
Spalding University, Louisville, KY 
  
CLINICAL EXPERIENCE 
 
7/2010 to    Predoctoral Psychology Intern  
present   Geisinger Medical Center, Danville, PA 
    
9/2008 to 12/2009 Psychotherapist, Psycho-Oncology Service 
   Indiana University Simon Cancer Center, Indianapolis, IN 
    
9/2007 to 7/2008 Psychotherapist, Adult Psychiatry Outpatient Clinic 
 Indiana University School of Medicine, IUPUI, Indianapolis, IN  
    
1/2007 to 8/2007 Research Assistant, Psychotherapist 
   Richard L. Roudebush VA Medical Center, Indianapolis, IN   
 101 
8/2006 to 2/2007 Neuropsychology Assistant 
Neuropsychology Clinic, Department of Psychiatry, Indiana 
University School of Medicine, IUPUI, Indianapolis, IN 
 
AWARDS 
 
2011 Clinical Psychology Award for Research Excellence, Indiana 
University Purdue University Indianapolis.  
 
2010 Indiana Psychological Association Student Poster Competition, 
First Place 
 
2007 - 2010 Predoctoral Fellowship: Training in Research for Behavioral 
Oncology and Cancer Control Program, Indiana University School 
of Nursing Funded by an R-25 CA 117865 training grant through 
the National Cancer Institute. PI: Victoria Champion. 
 
2007 Article of the Year Award, Journal of Psychiatric Nursing 
 
PUBLICATIONS 
 
Brown, L.F., Kroenke, K., Theobald, D., &Wu, J. (in press). Comparison of vitality scale 
and Fatigue Symptoms Inventory in assessing cancer-related fatigue. Supportive Care in 
Cancer. 
 
Bigatti, S.M, Brown, L.F., Steiner, J., Miller, K.D. (2011). Breast cancer in a wife: How 
husbands cope and how well it works. Cancer Nursing, 34, 3. 
 
Brown, L.F., Kroenke, K., Theobald, D., Wu, J., and Tu, W. (2010). The association of 
depression and anxiety with health-related quality of life in cancer patients with 
depression and/or pain. Psycho-Oncology, 19, 734-741. 
 
Brown, L.F., Davis, L.W.,  LaRocco, V A., & Strasburger, A. (2010). Participant 
perspectives on mindfulness meditation training for anxiety in schizophrenia.  American 
Journal of Psychiatric Rehabilitation. 
 
Brown, L.F. & Kroenke, K. (2009). Cancer-related fatigue and its associations with 
depression and anxiety: A systematic review. Psychosomatics, 50, 440-447. 
 
Davis, L.W., Strasburger, A.M., & Brown, L.F. (2007).  Mindfulness: An intervention 
for anxiety symptoms in schizophrenia. Journal of Psychiatric Nursing, 45, 23-29 
 
Brown, L.F. (2004). Psychology in a new light: Darwin’s influence in the century after 
The Origin of Species. The Journal of Graduate Liberal Studies, IX: 2, 23-47. 
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PAPER AND SYMPOSIA PRESENTATIONS 
 
Brown, L.F. (2010, November). Mindfulness-based stress reduction for persistent 
cancer-related fatigue: A pilot study. Symposium presentation at the Association for 
Behavioral and Cognitive Therapies annual convention, San Francisco, CA. 
 
Brown, L.F. (2010, October). Depression and cancer-related fatigue: A cross-lagged 
panel analysis of causal effects. Podium presentation at The 2nd International Cancer 
Fatigue Symposium, Montreal, Quebec. 
 
POSTER PRESENTATIONS 
 
Brown, L.F., Kroenke, K., Rand, K.L., Bigatti, S.M. (2010, October). Depression and 
cancer-related fatigue: A cross-lagged panel analysis of causal effects. Poster presented 
at The 2nd International Cancer Fatigue Symposium, Montreal, Quebec. 
 
Johns, S., Brown, L.F., Kroenke, K., Monahan, P., & Beck-Coon, K. (2010, May). An 
acceptance-based model for treatment of cancer-related fatigue. Poster presented at 
Indiana University Simon Cancer Center Cancer Research Day, Indianapolis, IN. 
 
Brown, L.F., Kroenke, K. &, Wu, J. (2010, February). Comparison of vitality scale and 
FSI in assessing cancer-related fatigue. Poster presented at American Psychosocial 
Oncology Society national conference, New Orleans, LA. 
 
Brown, L.F., Kroenke, K., Theobald, D., Wu, J., and Tu, W. (2009, May). The 
association of depression and anxiety with health-related quality of life in cancer 
patients. Poster presented at Indiana University Simon Cancer Center Cancer Research 
Day, Indianapolis, IN. 
 
Brown, L.F. & Bigatti, S.M. (2008, March). Differential relations of fatigue with 
psychological variables in patients with breast cancer and their spouses. Poster presented 
at the annual meeting of the Society of Behavioral Medicine, San Diego, CA. 
 
Davis, L.W. & Brown, L.F. (2008, April). Mindfulness targeting anxiety symptoms of 
persons with schizophrenia: Results of a pilot study. Poster presented at the 6th Annual 
Conference for Clinicians, Researchers, and Educators: Integrating Mindfulness-Based 
Interventions into Medicine, Health Care, and the Larger Society, Worcester, MA. 
 
Brown, L.F. (2007, November). Interest in mindfulness meditation training among older 
adults. Poster session presented at a national conference on contemplative practices, 
Meditation and Spirituality: Scientific, Conceptual, and Applied Perspectives, Indiana 
State University, Terre Haute, IN. 
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TEACHING EXPERIENCE 
 
March-April 2011 Instructor, Mindfulness-Based Stress Reduction, 8-week 
mindfulness meditation class for mental health practitioners. 
Division of Psychiatry, Geisinger Medical Center, Danville, PA 
 
Spring 2010 Instructor, B365, Stress and Health, Department of Psychology, 
IUPUI 
 
Fall & Spring Teaching Assistant, Introduction to Counseling classes 
2007-2008 Department of Psychology, IUPUI.  
  
Fall & Spring  Teaching Assistant, Psychology of Stress, Sports Psychology.  
2005-2006  Department of Psychology, IUPUI.   
 
RESEARCH EXPERIENCE 
 
1/2008 to present Pilot Study of Mindfulness-Based Stress Reduction for Patients 
with Persistent Cancer-Related Fatigue 
   Principle Investigator: Kurt Kroenke, M.D. 
Study Team: Shelley Johns, Linda F. Brown, Patrick Monahan, 
Kathleen Beck-Coon 
 
1/2008 to 2010 Depression and Cancer-Related Fatigue: 
  A Cross-Lagged Panel Analysis of Causal Effects 
   Primary Mentor: Kurt Kroenke, M.D. 
   Secondary Mentor: Silvia M. Bigatti, PhD 
 
7/2006 to 8/2007  Mental Health Treatment Study 
   Supervisors: Mike McKasson, LCSW; Roline Milfort, PhD 
 
1/2007 to 3/2008 Mindfulness as an Intervention for Anxiety Symptoms in 
Schizophrenia 
   Supervisor: Louanne Davis, PsyD 
 
3/2006 to 7/2007 Interest in Mindfulness Meditation Among Older Adults 
   Mentor, Principal Investigator: Silvia M. Bigatti, PhD 
 
OTHER WORK EXPERIENCE 
 
8/2005 to 5/2006 Graduate Assistant, Kelly School of Business, IUPUI 
   Supervisors:  Alexander Fedorikhin, PhD; Susan Mantel, PhD 
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Prior to Graduate School Admission 
 
2000 to 2005 Vice President of Human Resources, RiverValley Behavioral 
Health (Community Mental Health Center) 
   Owensboro, KY 
 
TRAINING IN SPECIAL INTEREST AREAS 
 
2009-2010 Teaching Apprenticeship in Mindfulness-Based Stress Reduction 
Mentor, Kathleen Beck-Coon, MD 
 28 hours of training and teaching experience over 10 weeks 
 Indiana University School of Nursing 
 
2009 Practicum in Mindfulness-Based Stress Reduction:  
Living Inside Participant-Practitioner Perspectives. 
 Melissa Blacker, MA & Florence Meleo-Meyer, MS, MA 
 9-day, 66-hour practicum 
 Center for Mindfulness, University of Massachusetts Medical 
School, Worcester, MA 
 
2008 Mindfulness-Based Stress Reduction in Mind-Body Medicine: 
A 7-Day Professional Training. 
 Jon Kabat-Zinn, PhD & Saki Santorelli, EdD 
 Center for Mindfulness, Rhinebeck, NY 
 
2008 Structural Equation Modeling with LISREL for Windows 
 Gregory Hancock, PhD & Ralph O. Mueller, PhD 
 3-Day Workshop 
 Chicago, IL 
 
2007 Acquiring Skills to Implement Acceptance and Commitment 
Therapy 
 Steven Hayes, PhD, 2-day workshop 
 Philadelphia, PA 
 
2007 Motivational Interviewing Workshop 
 John Wryobeck, PhD, 3-day workshop 
Indianapolis, IN 
 
PROFESSIONAL MEMBERSHIPS 
Association for Behavioral and Cognitive Therapies 
Association for Contextual Behavioral Science 
American Psychological Association, student affiliate 
American Psychology Association of Graduate Students 
Indiana Psychological Association 
